<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_ttDa2yy">Digital Health Interventions Are Effective for Irritable Bowel Syndrome Self-Management: A Systematic Review</title>
				<funder>
					<orgName type="full">IMAGINE</orgName>
				</funder>
				<funder ref="#_EWcY3GC">
					<orgName type="full">Canadian Institutes for Health Research (CIHR) Strategy for Patient-Oriented Research</orgName>
					<orgName type="abbreviated">SPOR</orgName>
				</funder>
				<funder>
					<orgName type="full">Svare Chair in Health Economics</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">© The Author(s) 2024</p>
				</availability>
				<date type="published" when="2024-10-14">14 October 2024</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Adrijana</forename><surname>D'silva</surname></persName>
							<email>adrijana.dsilva@ucalgary.ca</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Community Health Sciences , Cumming School of Medicine , University of Calgary , Calgary , Alberta , Canada</note>
								<orgName type="department" key="dep1">Department of Community Health Sciences</orgName>
								<orgName type="department" key="dep2">Cumming School of Medicine</orgName>
								<orgName type="institution">University of Calgary</orgName>
								<address>
									<settlement>Calgary</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicolle</forename><surname>Hua</surname></persName>
							<email>nicolle.hua@ucalgary.camaryv.modayilmary.modayil@albertahealthservices.ca</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Community Health Sciences , Cumming School of Medicine , University of Calgary , Calgary , Alberta , Canada</note>
								<orgName type="department" key="dep1">Department of Community Health Sciences</orgName>
								<orgName type="department" key="dep2">Cumming School of Medicine</orgName>
								<orgName type="institution">University of Calgary</orgName>
								<address>
									<settlement>Calgary</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mary</forename><forename type="middle">V</forename><surname>Modayil</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Primary Health Care , Alberta Health Services , Edmonton , Alberta , Canada</note>
								<orgName type="department">Primary Health Care</orgName>
								<orgName type="institution">Alberta Health Services</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Judy</forename><surname>Seidel</surname></persName>
							<email>judy.seidel@albertahealthservices.ca</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Community Health Sciences , Cumming School of Medicine , University of Calgary , Calgary , Alberta , Canada</note>
								<orgName type="department" key="dep1">Department of Community Health Sciences</orgName>
								<orgName type="department" key="dep2">Cumming School of Medicine</orgName>
								<orgName type="institution">University of Calgary</orgName>
								<address>
									<settlement>Calgary</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Primary Health Care , Alberta Health Services , Edmonton , Alberta , Canada</note>
								<orgName type="department">Primary Health Care</orgName>
								<orgName type="institution">Alberta Health Services</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Deborah</forename><forename type="middle">A</forename><surname>Marshall</surname></persName>
							<email>damarsha@ucalgary.ca</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Community Health Sciences , Cumming School of Medicine , University of Calgary , Calgary , Alberta , Canada</note>
								<orgName type="department" key="dep1">Department of Community Health Sciences</orgName>
								<orgName type="department" key="dep2">Cumming School of Medicine</orgName>
								<orgName type="institution">University of Calgary</orgName>
								<address>
									<settlement>Calgary</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Adrijana</forename><forename type="middle">D '</forename><surname>Silva</surname></persName>
						</author>
						<title level="a" type="main" xml:id="_hvfnuJN">Digital Health Interventions Are Effective for Irritable Bowel Syndrome Self-Management: A Systematic Review</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2024-10-14">14 October 2024</date>
						</imprint>
					</monogr>
					<idno type="MD5">CD1D833F35475B1ED8EBBFDCF4F2E5E3</idno>
					<idno type="DOI">10.1007/s10620-024-08672-7</idno>
					<note type="submission">Received: 19 July 2024 / Accepted: 26 September 2024 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_6mrmfkw">Irritable bowel syndrome</term>
					<term xml:id="_vAavSjt">Digital health</term>
					<term xml:id="_xaHdvf3">Self-management</term>
					<term xml:id="_tp3eSGJ">Systematic review</term>
					<term xml:id="_KHbh4eK">Effectiveness</term>
					<term xml:id="_kfACcSe">Feasibility</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_agUjmXy"><p xml:id="_KPpvX7q"><s xml:id="_8cMUS3W">Background Digital health interventions (DHIs) could be a valuable self-management tool for patients with irritable bowel syndrome (IBS), but little research exists on IBS-focused DHIs and their effectiveness.</s><s xml:id="_6UckQq9">This review aimed to identify DHIs for IBS and evaluate their characteristics, effectiveness, and feasibility.</s><s xml:id="_X4JJCqE">Methods Our study team, including patient partners, conducted a systematic review using Medline, PsycINFO, Embase, Web of Science, and CINAHL from database inception to May 2024.</s><s xml:id="_UHzMHG3">Experimental and observational studies evaluating DHIs designed for use by IBS patients were included.</s><s xml:id="_xvKyadM">Data extraction and assessment included study and DHI characteristics, effectiveness outcomes (symptom severity, quality of life, psychological indices, patient empowerment), and feasibility measures (adherence, usability, user satisfaction).</s><s xml:id="_zHGH8Vt">Study quality and bias were assessed using a modified checklist of Downs and Black.</s><s xml:id="_Qwcz6d5">Results Of the 929 identified, 13 studies of DHIs were included and deemed good quality on average (21,510 total participants) with six primary areas of focus: education, diet, brain-gut behavior skills, physiological support, health monitoring, and community engagement.</s><s xml:id="_R4zpkJS">Most DHIs were self-directed and reported statistically significant improvements in most effectiveness outcomes.</s><s xml:id="_scR9B3s">Evidence suggests that DHIs focusing on brain-gut behavior skills or health monitoring may be most effective compared to other types of DHIs.</s><s xml:id="_GErMFWu">However, their feasibility remains unclear, and the generalization of their impacts is limited.</s><s xml:id="_gMymySB">Conclusion This review underscores the potential of DHIs in supporting IBS patients and improving their outcomes.</s><s xml:id="_VH55XrW">However, additional research is warranted for continued intervention use in this population, including assessments on feasibility, safety, cost-effectiveness, and patient empowerment and experiences.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="21" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dQFSUrp">Introduction</head><p xml:id="_yBNd2ZX"><s xml:id="_dSVuHav">Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction, characterized by abnormal changes in bowel habits, abdominal pain and bloating, and associated psychiatric conditions and an estimated prevalence of 9.2% worldwide <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s xml:id="_scgpB6v">Self-management-through consistent adherence to dietary modifications and psychological and pharmacological therapies-could effectively mitigate IBS symptoms, alleviate healthcare burden, and improve patient quality of life <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>.</s></p><p xml:id="_zkRYUWz"><s xml:id="_v2cAjp7">Digital health interventions (DHIs) developed for persons are defined as discrete digital technologies designed to be functionally capable of addressing personal challenges, such as members of the public who are potential or current users of health services and caregivers of individuals experiencing challenges with receiving health services <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s xml:id="_cjUNubW">DHIs have become valuable resources for patients to self-manage symptoms and comorbidities in the form of mobile applications and web-based programs, providing them access to clinical and actionable content to improve disease-related knowledge and outcomes <ref type="bibr" target="#b7">[8]</ref>.</s><s xml:id="_wtbASsz">The design and function of DHIs typically fall into one or multiple categories: symptom tracking, patient-and community-based resources, telemedicine, and connection to digital and wearable devices <ref type="bibr" target="#b8">[9]</ref>.</s></p><p xml:id="_6MDkRUe"><s xml:id="_9dUpY3h">Despite growing research interest in the relationship between DHIs and GI health, existing reviews do not fully capture DHIs or their impacts on IBS, specifically.</s><s xml:id="_JCRMFJd">A 2018 systematic review and 2021 meta-analysis assessed the effectiveness of DHIs for participants with GI-related health conditions <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s xml:id="_CtYzskU">Both studies measured certain patient outcomes, providing a partial understanding of the effects of DHIs.</s><s xml:id="_DB7bkSv">A recently published systematic review assessed the current landscape of novel digital therapeutics for IBS that primarily focused on brain-gut behavior therapies <ref type="bibr" target="#b11">[12]</ref>, thus excluding DHIs that support other aspects of IBS self-management, such as diet and lifestyle changes <ref type="bibr" target="#b12">[13]</ref>.</s><s xml:id="_uV6T79x">Furthermore, feasibility is another crucial component in assessing the relevance and sustainability of an intervention <ref type="bibr" target="#b13">[14]</ref>, yet it was not explored in any of the mentioned reviews.</s></p><p xml:id="_RqPc7SD"><s xml:id="_mvgygE4">To our knowledge, there is no recent systematic review that identifies, summarizes, and evaluates the feasibility and effectiveness of DHIs in IBS.</s><s xml:id="_YzfymtD">This systematic review aimed to address this knowledge gap by: (1) identifying existing IBS-specific DHIs in the literature, <ref type="bibr" target="#b1">(2)</ref> assessing their effectiveness and feasibility in managing IBS, and (3) exploring potential correlations between DHI characteristics and effectiveness outcomes.</s><s xml:id="_YqCNfSf">Primary outcomes included IBS-related symptom severity, quality of life (QOL), psychological indices, patient empowerment, and feasibility-related measures (e.g., user satisfaction, adherence).</s><s xml:id="_nNxuEWw">We hypothesized that DHIs may significantly improve IBS patient outcomes and reflect high levels of feasibility.</s><s xml:id="_UUMuQDK">A better understanding of DHIs for self-management can inform patients, providers, researchers, and developers in advancing the quality, effectiveness, and accessibility of the current and future resources to improve patient outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WFP9rWj">Methodology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gx8W6Yx">Study Design and Strategy</head><p xml:id="_XxqZPYA"><s xml:id="_6Eau49X">This systematic review was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines <ref type="bibr" target="#b14">[15]</ref>.</s><s xml:id="_JrHDxnb">Data were retrieved from inception to May 24, 2024, using five electronic databases: Medline (OVID), PsycINFO, Web of Science, EMBASE (OVID), and CINAHL.</s><s xml:id="_mV3dJ7Y">The search strategy used a combination of the following MeSH headings and key terms (e.g., IBS, irritable bowel, mobile, digital, and eHealth), utilizing the "OR" and "AND" Boolean operators to broaden and narrow the search results, respectively (Supplementary File 1).</s><s xml:id="_cBgdCyB">Reference lists from eligible studies were examined to identify potential studies not captured from the search strategy, although none satisfied the inclusion criteria.</s><s xml:id="_ZhwpTWW">Excluded protocols were also further examined to identify potential articles that were subsequently published but were not captured from the search strategy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8mV9HmV">Study Selection</head><p xml:id="_xNq8wD9"><s xml:id="_V77tpRX">Records was stored, managed, and screened using Covidence <ref type="bibr" target="#b15">[16]</ref>.</s><s xml:id="_YAFjV26">After removing duplicate records, two reviewers [NH and CW] independently screened the titles and abstracts using an inclusion criteria (Supplementary File 2): experimental and observational studies that evaluated DHIs and their effectiveness outcomes, regardless of whether the DHI was developed by the respective study team or was a public or commercial product.</s><s xml:id="_HUUCc4a">The Population, Intervention, Comparison, and Outcome (PICO) characteristics for eligibility <ref type="bibr" target="#b16">[17]</ref> were as follows: (P) adults diagnosed with IBS; (I) DHIs designed for IBS patient use; (C) controls receiving no intervention (e.g., wait-list or usual care) or were included in a different program; and (O) quantitative, patient-reported effectiveness outcomes.</s><s xml:id="_GmQzcYJ">Disagreements between the two reviewers were resolved by consensus, and the remaining conflicts were resolved by a third party <ref type="bibr">[AD]</ref>.</s><s xml:id="_vPWu8rq">Abstracts satisfying the inclusion criteria by both reviewers were selected for full-text review.</s></p><p xml:id="_JtpVzYB"><s xml:id="_QRbEVN2">The full-text review was conducted independently by the same two reviewers, using an exclusion criteria (Supplementary File 2): (P) non-IBS patients, healthcare professionals, pediatric patients or caregivers of IBS, or adult patients in which their IBS diagnosis was not the primary focus of the study, (I) non-DHIs, DHIs that are not interventional, DHIs that were intended to compare different modes of delivery for the same treatment, DHIs of which are not the primary focus of the study itself, or internet-delivered cognitive behavioral therapies (iCBT) in the form of DHIs, (C) healthy populations, the use of other DHIs as controls, or the same treatment in a different mode of delivery, and (O) qualitative-based outcomes.</s><s xml:id="_TQrvbrB">Although iCBTs can be considered as DHIs, existing literature and reviews have already thoroughly assessed their effects on IBS <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b17">18]</ref>.</s><s xml:id="_qpDVaS5">Disagreements were resolved by consensus or escalated by a third party [AD] for a final decision.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gHavakD">Data Collection and Synthesis</head><p xml:id="_2GcvkUk"><s xml:id="_S5gP8ty">Data were extracted from full articles by NH and CW and reviewed by AD.</s><s xml:id="_YbKfhcU">A meta-analysis of the findings was planned to be undertaken should the results be sufficiently homogeneous.</s><s xml:id="_WF9CxqA">Characteristics of the study design collected include author, year, country, sample size, participant demographics, effectiveness outcomes, and significant findings.</s><s xml:id="_mDMUaNU">The primary outcomes of interest included IBSrelated symptom severity, QOL, psychological indices, patient empowerment, and feasibility-related measures (e.g., adherence, user satisfaction).</s><s xml:id="_arcWQgg">A p value less than 0.05 indicates a statistically significant difference in the values of the outcome measures <ref type="bibr" target="#b18">[19]</ref>.</s><s xml:id="_T6cF8Dx">DHIs were assessed for their characteristics, including the primary area of focus (education, diet, health monitoring, brain-gut behavior skills, physiological support, community engagement) (Table <ref type="table" target="#tab_0">1</ref>), features to prompt tool usage, professional support available for participants and their level of involvement (selfdirected or hybrid support), and level of personalization.</s><s xml:id="_enF44KN">Categorization of a DHI's "level of personalization" was defined by the study team as the DHI's capacity to allow data input and to generate personalized recommendations for IBS management; level "1" indicated no capacity to personalize (e.g., self-guided handbooks, educational resources, structured sessions), "2" indicated some capacity (e.g., health journals), and "3" indicated total capacity (e.g., artificial intelligence-based personalization, two-way communication with an involved professional).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QQRDQaN">Data Quality Assessment</head><p xml:id="_r5jXRad"><s xml:id="_PYgQupN">Study quality and risk of bias were assessed using a modified checklist from Downs and Black, removing irrelevant items and resulting in twelve criterions <ref type="bibr" target="#b19">[20]</ref>.</s><s xml:id="_v9SPpMS">The checklist criteria included study quality, internal validity and adjustment to confounding results, bias, and generalizability of results.</s><s xml:id="_bTfHWKU">The criteria were scored either "1" (satisfied) or "0" (unsatisfied or not reported).</s><s xml:id="_8VQugJs">Quality assessment was independently conducted by NH and CW, with disagreements resolved by consensus or a third opinion from AD, as needed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bFE5yx4">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jgYMBpZ">Study Identification</head><p xml:id="_w4YwxTp"><s xml:id="_nhw23qM">The PRISMA flow diagram (Fig. <ref type="figure" target="#fig_0">1</ref>) outlines the study identification and selection process, with a total of 13 studies selected for this review <ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref>.</s><s xml:id="_EMRbtGh">The initial compilation from the databases yielded 928 records, and de-duplication and application of the selection criteria resulted in 12 studies for the full-text review <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref>.</s><s xml:id="_TmkQFsd">One study was included separately from the database search after the study team assessed an excluded protocol article from the compilation list <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b33">34]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_wBcTChR">Participant and Study Characteristics</head><p xml:id="_tR82WCs"><s xml:id="_kte2yHB">General study characteristics are summarized in Table <ref type="table" target="#tab_1">2</ref>. Six studies were observational, and seven were experimental.</s><s xml:id="_S3NPXrY">No differences were observed between observational studies and randomized controlled trials, as studies of either design have demonstrated positive effects of DHIs among IBS patients.</s><s xml:id="_Hu4e5Ha">Half of the studies were conducted in North America (n = 7), while the remainder took place in Europe (n = 3), Asia (n = 2), and Australasia (n = 1).</s><s xml:id="_BpNDqDH">The cumulative sample size was 21,510 participants, ranging between 11 and 20,553.</s><s xml:id="_dCQTVep">The mean ages of participants varied from 20.4 (SD = 1.0) to 45.7 years (SD = 9.2).</s><s xml:id="_WgTPDGR">Intervention periods observed range between 12 days and three months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZkEbxpN">Digital Health Interventions</head><p xml:id="_wTKuZpX"><s xml:id="_9AKB8RE">Digital health intervention characteristics are summarized in Table <ref type="table" target="#tab_3">3</ref>.</s><s xml:id="_7n2QCpM">Of the 13 studies, six developed their DHIs.</s><s xml:id="_eY7eQmH">Most DHIs were accessed through mobile devices (n = 9), the web (n = 3), or both (n = 1).</s><s xml:id="_Ep9hAxd">The majority of DHIs included features to prompt and encourage participant engagement with the DHI and study (n = 7).</s><s xml:id="_FEsPUSU">Primary focus areas identified in the DHIs include education (n = 1), diet (n = 4), brain-gut behavior skills (n = 3), physiological support (n = 2), health monitoring (n = 2), and community engagement (n = 1).</s></p><p xml:id="_7Hy3yRP"><s xml:id="_uzMyR8Z">Both health monitoring DHIs focused on pain and symptoms, although Zia et al. included diet tracking <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b32">33]</ref>.</s><s xml:id="_kndkxma">The evaluated DHIs varied in levels of personalization and were largely self-directed.</s><s xml:id="_MWzKHVh">DHIs that primarily focus on brain-gut behavior skills and health monitoring were all associated with statistically significant improvements in effectiveness outcomes.</s><s xml:id="_QVbfKUA">Dietfocused DHIs indicated partially positive effects on the outcomes, although none assessed for psychological indices; symptom severity and quality of life were the common measures for diet-focused DHIs.</s><s xml:id="_PpMK6pD">These DHIs either focused  on food triggers and elimination diets <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>, which have reported conflicting results in IBS symptoms or on food items with low fermentable oligo-, di-, and monosaccharides and polyols (FODMAP) <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b29">30]</ref>, which yielded consistently positive results.</s><s xml:id="_rdd9xmz">Physiologically focused DHIs indicated conflicting effects on effectiveness outcomes.</s><s xml:id="_74cbtdr">Four DHIs were categorized as level "1" for their rigid and limited interface for users to input individualized data <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b30">31]</ref>.</s><s xml:id="_RBg3QT6">Five DHIs were categorized as personalization level "2" <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b32">33]</ref>; these interventions had some components of health monitoring to allow users to input and track their data.</s><s xml:id="_sMjqXxa">Lastly, three DHIs were considered level "3"; they included artificial intelligence technology to provide individualized recommendations <ref type="bibr" target="#b24">[25]</ref> and hybrid, two-way engagement designs to directly connect participants with a professional or person knowledgeable of the DHI or study <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b29">30]</ref>.</s></p><p xml:id="_DXQM3Tn"><s xml:id="_svy5ZFM">There were no observed differences in effects between self-directed and hybrid interventions on effectiveness outcomes.</s><s xml:id="_q2AhUXQ">Compared to DHIs with levels "2" or "3" in personalization, the DHIs categorized as level "1" were consistent in demonstrating statistically significant improvements for IBS symptoms, QOL, and psychological indices; three focused on brain-gut behavior skills <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29]</ref> and one on education <ref type="bibr" target="#b30">[31]</ref>.</s><s xml:id="_np2vUmc">No other notable correlations were observed between the effectiveness outcomes and the following aspects: incorporation of features to prompt and maintain user engagement; the type of DHI platform; and whether the DHI was self-directed or hybrid.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_385yvUU">Effects of DHIs on Patient Outcomes</head><p xml:id="_rtUjP4q"><s xml:id="_h4aa7fZ">Outcomes evaluating the effectiveness of DHIs included IBS-related symptom severity, QOL, psychological indices, and patient empowerment.</s><s xml:id="_UZ4ZpjA">A summary of the results is shown in Tables <ref type="table" target="#tab_4">4</ref> and <ref type="table" target="#tab_5">5</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KFKF8sj">Symptom Severity</head><p xml:id="_ZgnwR3h"><s xml:id="_Y2w28A4">All 13 studies evaluated IBS symptom severity.</s><s xml:id="_YbKdJZG">Ten studies noted statistically significant improvements in IBS symptom scores over the study period.</s><s xml:id="_52FwgMF">The use of the IBS Symptom Severity Scale (IBS-SSS) was most prevalent <ref type="bibr" target="#b34">[35]</ref>, although alternative instruments included the Functional Bowel Disorder Severity Index (FBDSI) <ref type="bibr" target="#b35">[36]</ref>, GI Symptom Rating Scale (GSRS-IBS) <ref type="bibr" target="#b36">[37]</ref>, and Subject's Global Assessment (SGA) of Relief <ref type="bibr" target="#b37">[38]</ref>.</s><s xml:id="_rKRmCnJ">In addition to the IBS-SSS, Jactel et al. also used the Patient Simple Clinical Colitis Activity Index (P-SCCAI) and the Mobile Health Index for Crohn's Disease (mHI-CD) to capture symptoms of IBS participants with comorbid inflammatory bowel disease (IBD) <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40]</ref>.</s><s xml:id="_pSRmuFW">Four studies developed their own measures to evaluate abdominal pain <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s xml:id="_mFNP763">Although Dorn et al. noted</s></p><p xml:id="_HK66zZj"><s xml:id="_KhWFUaX">Table 2 (continued) Study Study design Country Study duration Mean age (s.d.) (years) Sample size Male (%) IBS subtypes Digital health intervention Categories of measured outcomes Zia et al. (2016) [33] Observational crosssectional USA 2 weeks 35 (11) 11 27 IBS-D IBS-C IBS-M Health diary Feasibility Symptoms IQR interquartile range, s.d standard deviation, CBT cognitive behavioral therapy</s></p><p xml:id="_wskJgna"><s xml:id="_9vd7YPg">incorporating the FBDSI into their baseline survey, no raw data were reported <ref type="bibr" target="#b21">[22]</ref>.</s><s xml:id="_3KJBxmc">FBDSI scores was also not collected at the end of their study period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_wsZaQEx">Health-Related Quality of Life (QOL)</head><p xml:id="_Qf3t2JS"><s xml:id="_9VumTvg">Seven studies measured QOL, with six reporting statistically significant improvements.</s><s xml:id="_Ps4skG5">Jactel et al. indicated "strong improvements" but no statistical confirmation <ref type="bibr" target="#b24">[25]</ref>.</s><s xml:id="_5SvCW5q">The IBS-QOL Questionnaire was used most commonly <ref type="bibr" target="#b40">[41]</ref>, in addition to the World Health Organization's Quality of Life (WHOQOL) assessment <ref type="bibr" target="#b41">[42]</ref> and a 5-point Likert scale.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_BEDqB6K">Psychological Indices</head><p xml:id="_PVyQDTu"><s xml:id="_cBYk7Sf">Five studies measured psychological indices, with statistically significant improvements observed in most.</s><s xml:id="_t2WA3TU">However, the online yoga program from D'Silva et al. did not report significant changes in depression nor anxiety scores compared to the control <ref type="bibr" target="#b22">[23]</ref>.</s><s xml:id="_dAe2R7k">Various psychometric instruments assessed these indices, including the Hospital Anxiety and Depression Scale (HADS) <ref type="bibr" target="#b42">[43]</ref>, Fear of Food Questionnaire (FFQ) <ref type="bibr" target="#b43">[44]</ref>, Visceral Sensitivity Index (VSI) <ref type="bibr" target="#b44">[45]</ref>, Cognitive Scale for Functional Bowel Disorders (CSFBD) <ref type="bibr" target="#b45">[46]</ref>, Patient Health Questionnaire 9 (PHQ-9) and 15 (PHQ-15) <ref type="bibr" target="#b46">[47,</ref><ref type="bibr" target="#b47">48]</ref>, General Anxiety Disorder 7 <ref type="bibr" target="#b48">[49]</ref>, Gastrointestinal-Cognition domains "bowel frequency (during the day/night)," "general well-being," "urgency of defecation," and "extracolonic features"; mHI-CD Mobile Health Index for Crohn's Disease, cumulative score ranges between 0 = "no disease activity" and 14.29 = "extremely high disease activity"; IBS-QOL IBS Quality of Life, score ranges between 0 and 100 with higher scores indicating better quality of life, increase of &gt; 10 points considered clinically significant; WHO-QOL World Health Organization Quality of Life Questionnaire, score ranges between 0 = "very poor quality of life" and 100 = "best possible quality of life"; PHQ-9 Patient health questionnaire-9, cumulative score ranges between 0 and 27, score grades of increasing severity (0-4, 5-9, 10-14, 15-19, ≥ 20);</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FpygfeG">PHQ-15</head><p xml:id="_Adav78h"><s xml:id="_DjJGRW2">Patient Health Questionnaire-15, 0 = "not bothered at all" to 2 = "bothered a lot," cumulative score ranges minimal (0-4), mild (5-8), moderate <ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref>, and high <ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref><ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref>; SGA Subjects Global Assessment of Relief, score ranges between 1 = "completely relieved" and 5 = "worse," participants are grouped as either "responders" = [≥ 50% of responses reporting "considerably relieved"/"completely relieved" or at least "somewhat relieved" 100% of responses] or "non-responders"; DASS Depression Anxiety Stress Scale, individual scores for anxiety, stress, and depression categories with different score ranges of severity; CSFBD Cognitive Scale for Functional Bowel Disorders; total score ranges between 31 and 217, higher scores indicate greater dysfunctional thoughts; PCS Pain Catastrophizing Scale, cumulative score ranges between 0 = "no catastrophic thoughts" and 52 = "extremely high levels of catastrophizing, 30 considered threshold for clinically relevant level of catastrophizing; VSI Visceral Sensitivity Index, 0 = "strongly disagree" to 5 = "strongly agree," cumulative score ranges minimal or mild (0-10), moderate <ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref><ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>, and severe (31-75); GI-COG Gastrointestinal Cognitions Questionnaire, 0 = "hardly" to 4 = "very much," cumulative score ranges minimal or mild (0-19), moderate <ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b30">(31)</ref><ref type="bibr" target="#b31">(32)</ref><ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref><ref type="bibr" target="#b35">(36)</ref><ref type="bibr" target="#b36">(37)</ref><ref type="bibr" target="#b37">(38)</ref><ref type="bibr" target="#b38">(39)</ref>, and severe ; FFQ Fear of Food Questionnaire, 0 = "not at all" to 5 = "absolutely", cumulative score grades minimal (0-15), mild <ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref><ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>, moderate <ref type="bibr" target="#b30">(31)</ref><ref type="bibr" target="#b31">(32)</ref><ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref><ref type="bibr" target="#b35">(36)</ref><ref type="bibr" target="#b36">(37)</ref><ref type="bibr" target="#b37">(38)</ref><ref type="bibr" target="#b38">(39)</ref><ref type="bibr" target="#b39">(40)</ref><ref type="bibr" target="#b40">(41)</ref><ref type="bibr" target="#b41">(42)</ref><ref type="bibr" target="#b42">(43)</ref><ref type="bibr" target="#b43">(44)</ref><ref type="bibr" target="#b44">(45)</ref>, and severe (46-90); FMI-SF Freiburg Short Form Mindfulness Questionnaire, 14 items ranging between 1 = "rarely" and 4 = "almost always," cumulative score ranges 14-56 with higher scores indicating greater levels of mindfulness; PSS Perceived stress scale, 0 = "never" to 4 = "very often," score ranges between 0 and 40 with higher scores indicating lower levels of perceived stress; CSS</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_X2R2pbn">COVID-19 Stress</head><p xml:id="_7VdbY5X"><s xml:id="_33ArEx3">Scale, 0 = "not at all/never" to 4 = "extremely/almost always," higher scores indicate higher levels of COVID-19-related stress and anxiety; VAS visual analog scale, score ranges between 0 and 100, use of this measure and interpretation of scores dependent on study  <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b51">52]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_46EvEuU">Patient Empowerment</head><p xml:id="_T2G8Cvm"><s xml:id="_XdnpPPf">Three studies measured patient empowerment, which included patient knowledge (n = 1), activation (n = 1), or both (n = 1).</s><s xml:id="_23u3ys2">Validated instruments included the Patient Activation Measure (PAM) <ref type="bibr" target="#b52">[53]</ref>, Patient Enablement Instrument (PEI) <ref type="bibr" target="#b53">[54]</ref>, and the Low FODMAP Diet Knowledge (LFDK) questionnaire <ref type="bibr" target="#b54">[55]</ref>.</s><s xml:id="_TBsYEYN">Dorn et al. and Jactel et al. quantified patients' knowledge of IBS, using the 100-mm visual analog and 5-point Likert scales, respectively <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s xml:id="_dfWyBnf">Patient empowerment was challenging to assess across studies due to the variability in how instruments assessed this construct.</s><s xml:id="_U78cEXD">Dorn et al. reported a statistically significant increase in patient knowledge, yet no statistically significant difference in PAM scores <ref type="bibr" target="#b21">[22]</ref>.</s><s xml:id="_NmykwpZ">Jactel et al. also noted "strong improvements" in their patient empowerment scores, yet statistical confirmation was not reported <ref type="bibr" target="#b24">[25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_SBt327h">Feasibility Measures</head><p xml:id="_dTXpT3Y"><s xml:id="_Tb3tdfG">Seven studies assessed the feasibility of their DHIs (Table <ref type="table" target="#tab_7">6</ref>).</s><s xml:id="_CUDBUrX">The definition of feasibility and associated instruments varied significantly among the studies.</s><s xml:id="_KED6Vdn">Measures were grouped into two categories: (1) adherence, compliance, and attrition and (2) usability and satisfaction with the DHI.</s><s xml:id="_PNkVh3d">Adherence, compliance, and attrition were measured using mathematical calculations and thresholds established by study teams, although one study based their questionnaire on the NHANES food frequency questionnaire <ref type="bibr" target="#b55">[56]</ref>.</s><s xml:id="_qqBJfA5">Conversely, measurements on usability and satisfaction were more consistent; the System Usability Scale (SUS) <ref type="bibr" target="#b56">[57]</ref>, User Burden Scale (UBS) <ref type="bibr" target="#b57">[58]</ref>, and net promoter scale <ref type="bibr" target="#b58">[59]</ref> were used to quantify the DHIs' usability, burden, and user satisfaction, respectively.</s><s xml:id="_86bJdhE">Adherence and compliance were determined by the completion percentage or the activity frequency.</s><s xml:id="_rFmbxbP">Nine studies reported varying rates of adherence and attrition with the DHI over time <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b32">33]</ref>.</s><s xml:id="_tdsPKjC">Oerlemans et al. considered the completion of their PDA health diary feasible for the short term (4 weeks) but not in the long term (3-month follow-up) due to a high participant dropout rate <ref type="bibr" target="#b26">[27]</ref>.</s><s xml:id="_GHsFqm4">Similarly, Pathipati et al. and Peters et al. reported high attrition of users over the course of their studies <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s xml:id="_gPncyq5">Hunt et al. also reported a low average of completed modules and significant attrition associated with more severe scores of visceral sensitivity and fear of food within the eight-week period <ref type="bibr" target="#b23">[24]</ref>.</s><s xml:id="_UJFpxMy">However, they noted that the 14 additional participants who were lost to follow-up prior to the 3-month assessment correlated with improved psychological indices <ref type="bibr" target="#b23">[24]</ref>.</s><s xml:id="_DyX4CKe">Two studies that assessed effectiveness outcomes in relation to adherence observed little correlations between the two <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s xml:id="_YveDJwq">However, factors contributing to lower adherence and higher attrition rates were not explored in the studies.</s></p><p xml:id="_fmhFzJb"><s xml:id="_FsNjhby">Four studies that evaluated DHI usability and desirability noted high scores and low user burden <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b32">33]</ref>.</s><s xml:id="_kamyNYJ">In one study, participants who have used the DHI's reminder function reported higher SUS scores compared to those who did not, yet no significant difference in compliance rates were observed between the two cohorts <ref type="bibr" target="#b32">[33]</ref>.</s></p><p xml:id="_fy46u3X"><s xml:id="_Esz4BXB">No study explored correlations between user satisfaction, desirability, and adherence and compliance.</s></p><p xml:id="_PAZ6UhS"><s xml:id="_ygTrUEb">Table 5 (continued) NA Not applicable, s.d.</s><s xml:id="_UQbJjBG">standard deviation IBS-SSS IBS symptom severity scale, score ranges between 0 and 500, score ranges mild , moderate (175-299), and severe (300-500), decrease of &gt; 50 points considered clinically significant; GSRS-IBS Gastrointestinal Symptom Rating Scale-IBS, 1 = "no discomfort at all" to 7 = "very severe discomfort," total score ranges between 0 and 78; IBS-QOL IBS Quality of Life, score ranges between 0 and 100 with higher scores indicating better quality of life, increase of &gt; 10 points considered clinically significant; WHO-QOL World Health Organization Quality of Life Questionnaire, score ranges between 0 = "very poor quality of life" and 100 = "best possible quality of life"; PHQ-9 Patient health questionnaire-9, cumulative score ranges between 0 and 27, score grades of increasing severity (0-4, 5-9, 10-14, 15-19, ≥ 20); PHQ-15 Patient Health Questionnaire-15, 0 = "not bothered at all" to 2 = "bothered a lot," cumulative score ranges minimal (0-4), mild (5-8), moderate <ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref><ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref>, and high <ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref><ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref>; DASS Depression Anxiety Stress Scale, individual scores for anxiety, stress, and depression categories with different score ranges of severity; CSFBD Cognitive Scale for Functional Bowel Disorders; total score ranges between 31 and 217, higher scores indicate greater dysfunctional thoughts; PCS Pain Catastrophizing Scale, cumulative score ranges between 0 = "no catastrophic thoughts" and 52 = "extremely high levels of catastrophizing, 30 considered threshold for clinically relevant level of catastrophizing; VSI Visceral Sensitivity Index, 0 = "strongly disagree" to 5 = "strongly agree," cumulative score ranges minimal or mild (0-10), moderate <ref type="bibr" target="#b10">(11)</ref><ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref><ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>, and severe ; GI-COG Gastrointestinal Cognitions Questionnaire, 0 = "hardly" to 4 = "very much," cumulative score ranges minimal or mild (0-19), moderate <ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref><ref type="bibr" target="#b30">(31)</ref><ref type="bibr" target="#b31">(32)</ref><ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref><ref type="bibr" target="#b35">(36)</ref><ref type="bibr" target="#b36">(37)</ref><ref type="bibr" target="#b37">(38)</ref><ref type="bibr" target="#b38">(39)</ref>, and severe ; FFQ Fear of Food Questionnaire, 0 = "not at all" to 5 = "absolutely," cumulative score grades minimal (0-15), mild <ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref><ref type="bibr" target="#b18">(19)</ref><ref type="bibr" target="#b19">(20)</ref><ref type="bibr" target="#b20">(21)</ref><ref type="bibr" target="#b21">(22)</ref><ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref><ref type="bibr" target="#b25">(26)</ref><ref type="bibr" target="#b26">(27)</ref><ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>, moderate <ref type="bibr" target="#b30">(31)</ref><ref type="bibr" target="#b31">(32)</ref><ref type="bibr" target="#b32">(33)</ref><ref type="bibr" target="#b33">(34)</ref><ref type="bibr" target="#b34">(35)</ref><ref type="bibr" target="#b35">(36)</ref><ref type="bibr" target="#b36">(37)</ref><ref type="bibr" target="#b37">(38)</ref><ref type="bibr" target="#b38">(39)</ref><ref type="bibr" target="#b39">(40)</ref><ref type="bibr" target="#b40">(41)</ref><ref type="bibr" target="#b41">(42)</ref><ref type="bibr" target="#b42">(43)</ref><ref type="bibr" target="#b43">(44)</ref><ref type="bibr" target="#b44">(45)</ref>, and severe (46-90); FMI-SF Freiburg Short Form Mindfulness Questionnaire, 14 items ranging between 1 = "rarely" and 4 = "almost always," cumulative score ranges 14-56 with higher scores indicating greater levels of mindfulness; PSS Perceived stress scale, 0 = "never" to 4 = "very often," score ranges between 0 and 40 with higher scores indicating lower levels of perceived stress; CSS COVID-19 Stress Scale, 0 = "not at all/never" to 4 = "extremely/almost always," higher scores indicate higher levels of COVID-19-related stress and anxiety  Assessment of harm (Number of adverse events from intervention)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YPgThVz">Safety</head><p xml:id="_hCtFA4Y"><s xml:id="_nVPBPkX">No adverse or safety events reported.</s></p><p xml:id="_tMY6SrY"><s xml:id="_y5Gfcba">Program satisfaction (Overall rating between 1 (strongly disagree) and 7 (strongly agree), satisfaction achieved at threshold of 70% of satisfied participants) Desirability &amp; Satisfaction 41% rated the program as "excellent," 30% as "great," 29% as "good".</s><s xml:id="_X5SHJnx">52% of participants strongly agreed that they would recommend the intervention to others.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_uyPa9TJ">Hunt et al. (2021) [24]</head><p xml:id="_erXjsuU"><s xml:id="_zPnBDZQ">Adherence "dose" (Number of modules in the intervention completed)</s></p><p xml:id="_6NTkhYr"><s xml:id="_3JWbkFZ">Adherence &amp; Attrition Average of three (Mean 3.2, s.d. 2) of eight modules completed by majority of the immediate intervention group.</s></p><p xml:id="_g8UNNqd"><s xml:id="_zVFgwth">Of the initial 121 participants recruited, 80 participants from the intervention (n = 36) and control (n = 44) groups completed the 8-week assessment.</s></p><p xml:id="_r26zTFM"><s xml:id="_3yJDr8B">Of the 106 participants from the intervention (n = 62) and crossedover control (n = 44) groups, 59 participants (56%) completed the post-treatment assessment.</s></p><p xml:id="_mNJUssG"><s xml:id="_5NbAy3x">Fourteen of the remaining 59 participants (24%) who completed the post-treatment assessment were lost to follow-up prior to the 3-month re-assessment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XAw6KaD">Jactel et al. (2022) [25]</head><p xml:id="_XnwmdXY"><s xml:id="_Gb89Jw8">Engagement (Daily completion of surveys and participant retention)</s></p><p xml:id="_a8P6bah"><s xml:id="_yJqwcSD">Adherence &amp; Attrition 95% participant retention from baseline to end of the study period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_WTk6YTH">NPS</head><p xml:id="_wafMs3c"><s xml:id="_TKXvE2m">Desirability &amp; satisfaction 92% of participants reported satisfaction with the intervention.</s></p><p xml:id="_XzzZa9j"><s xml:id="_Xwz4cDq">Adherence (Percentage of trigger food intake reduction and number of days compliant to intervention's recommendations)</s></p><p xml:id="_tNsTdGu"><s xml:id="_GrNMJuC">Adherence &amp; attrition 89% of participants adhered partially or fully to the intervention.</s><s xml:id="_rjezh5d">Table 6 (continued) Study, year Feasibility outcome measure Type of feasibility Findings Rafferty et al. (2021) [30] LFDA Adherence &amp; Attrition Mean 65.6 (s.d.</s><s xml:id="_W4attXX">26.6).</s><s xml:id="_qHGR4TA">Only the median changes and interquartile ranges of outcome measure scores were reported; raw scores at the end of the intervention period and p values between baseline and end-of-study scores were not reported: LFDA = -14.0</s><s xml:id="_bd8857F">(141.4,</s><s xml:id="_Y4hsUJj">3.3).</s><s xml:id="_xdjqFCb">Difference in the changes in LFDA scores between control and intervention groups was not statistically significant.</s><s xml:id="_3HvqxyW">Zia et al. (2016) [33] Completion rates (Number of actual entries over minimum requested entries) Adherence &amp; Attrition Meals: 112% (s.d.</s><s xml:id="_jx8EbTk">47), rates exceeded 100% for 55% of participants.</s><s xml:id="_cwMjNbh">GI symptoms: 78% (s.d.</s><s xml:id="_DcjrXhU">44).</s><s xml:id="_GasCZ5B">Difference in completion rates between meals and GI symptoms journal entries was not statistically significant.</s><s xml:id="_yEG837t">Mean decrease: meals = 25% (s.d.</s><s xml:id="_uwVTMce">39), GI symptoms = 17% (s.d.</s><s xml:id="_D7UcWc9">42).</s><s xml:id="_yB69SuP">SUS Desirability &amp; Satisfaction Mean 83 (No s.d.).</s><s xml:id="_9K4XKd4">Higher SUS score reported in participants who used the optional reminder function (Mean 92, s.d.</s><s xml:id="_FYvy3jq">3.8) compared to those who did not (Mean 79, s.d.</s><s xml:id="_3n4yj5T">11.7).</s><s xml:id="_vsxJHWS">Compliance (Number of actual entries completed within a 12 and 24 h reported time-window out of the total number of entries) Adherence &amp; Attrition Meals: 83% (s.d. 25, 12 h) in 12 h, 90% (s.d.</s><s xml:id="_4vVYPw3">19, 24 h).</s><s xml:id="_Db4Xk3w">GI Symptoms: 88% (s.d.</s><s xml:id="_X4nNHPT">17, 12 h), 94% (s.d. 12, 24 h).</s><s xml:id="_bbhwcMr">Difference in compliance rates between meal and GI symptom journal entries was not statistically significant.</s><s xml:id="_CqNA7PY">Mean decrease (24 h): meals = 5% (s.d.</s><s xml:id="_GjCHpVK">33), GI symptoms = 8% (s.d.</s><s xml:id="_9bnEx8e">31).</s><s xml:id="_6hZqpDn">Difference in compliance rates between participant cohorts that used and did not use the optional reminder function was not statistically significant.</s></p><p xml:id="_cguZjWt"><s xml:id="_y7G3qgQ">Overall feasibility (Percentage of participants with average daily completion and 24-h compliance rates of ≥ 50%)</s></p><p xml:id="_vHVNXnG"><s xml:id="_ev8hbzY">Adherence &amp; Attrition 73% of participants met overall feasibility threshold.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_93Af58A">s.d. standard deviation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_csjNWtg">SUS</head><p xml:id="_4tnu8HE"><s xml:id="_q85U6fw">Sytem usability scale, score ranges between 0 and 100, threshold of 68 = "average," scores &gt; 68 = "above average" or positive usability experiences, and scores &lt; 68 = "below average" or negative usability experiences; UBS User Burden Scale, cumulative score ranges between 0 = "no burden" and 80 = "extremely high burden; NPS Net Promoter Scale, score ranges between -100 and 100, score &gt; 0 considered "good", &gt; 50 considered "exceptional"; LFDA Low FODMAP Diet Adherence, score ranges between 0 = "no FODMAP eaten in past month" and 385 = "every FODMAP was eaten 2-3 times per day or more"</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4JwgP6U">Study Quality Assessment</head><p xml:id="_pZjYk5Z"><s xml:id="_qYzR6wv">Study quality scores ranged from 5 to 12, with an average rating of 8.8, indicating good quality overall (Supplementary File 3).</s><s xml:id="_FhycCg9">However, the assessment indicated a higher risk of bias, with ten studies (77%) providing unclear or no information on the use of statistical methods to address the confounding.</s><s xml:id="_5UtJy5V">Eight (62%) also did not report specific time periods for participant recruitment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UNYp2C2">Discussion</head><p xml:id="_usm9sn7"><s xml:id="_P32Rz8g">Our review provides the most recent and comprehensive summary and evaluation of studies examining DHIs to support the self-management of IBS.</s><s xml:id="_9eFDcKE">Compared to previous systematic reviews on DHIs for IBS, this review is the first to collectively assess symptom severity, QOL, psychological indices, patient empowerment, and feasibility and explore potential correlations between DHI characteristics and effectiveness outcomes.</s><s xml:id="_WkYA6ac">There is supporting evidence for the use of DHIs for IBS patients in improving GI-related symptoms, QOL, and psychological indices; conversely, there is limited and conflicting evidence to support feasibility and improvements in patient empowerment.</s><s xml:id="_9XwYj55">Since research on IBS is limited and underrepresented, our comparisons are made to other chronic GI conditions that have been researched more extensively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qYp3s5b">Effects of DHIs on Patient Outcomes</head><p xml:id="_Bs6jRKU"><s xml:id="_f5bN9g6">Findings from our review indicate that DHIs effectively improve IBS symptoms and QOL, which is consistent with reviews on IBD-focused DHIs that share similar features, particularly symptom monitoring <ref type="bibr" target="#b59">[60]</ref>.</s><s xml:id="_aMZpzQq">Similarly, other systematic reviews and meta-analyses among patients with IBD, celiac disease, and chronic pain found significant improvements in QOL <ref type="bibr" target="#b60">[61]</ref><ref type="bibr" target="#b61">[62]</ref><ref type="bibr" target="#b62">[63]</ref><ref type="bibr" target="#b63">[64]</ref>, while one study did not <ref type="bibr" target="#b64">[65]</ref>.</s><s xml:id="_sNgTz8Y">The evidence is supportive of improvements in psychological distress as demonstrated by four of the five included studies <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b31">32]</ref>, although these outcomes were not extensively evaluated compared to IBS symptoms and QOL.</s><s xml:id="_tnqnQbS">In contrast, Rohde et al. reported conflicting and limited evidence to suggest DHIs improve psychological distress in the IBD population, but these outcomes warrant further investigation <ref type="bibr" target="#b10">[11]</ref>.</s><s xml:id="_BJjM6ZS">Interestingly, two of the three studies reported conflicting evidence of improvements in patient empowerment, specifically user knowledge and activation, regardless of study quality.</s><s xml:id="_hcaCRnZ">Conversely, a mixed-methods systematic review on IBD participants indicated that, despite reported challenges of using DHIs, most conferred their benefits, including improved disease-related knowledge, enhanced communication with their providers, and a greater sense of reassurance <ref type="bibr" target="#b61">[62]</ref>.</s><s xml:id="_X34QgDV">Although patient empowerment is an essential catalyst for promoting self-management practices and behaviors <ref type="bibr" target="#b65">[66,</ref><ref type="bibr" target="#b66">67]</ref>, evaluation of this outcome is limited, and further research is needed to address this knowledge gap.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PgTGDzP">Correlations Between DHI Characteristics and Effectiveness Outcomes</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_6pZ5ESZ">Focus Area</head><p xml:id="_2QthMFe"><s xml:id="_CdWQqa4">The positive improvements in effectiveness outcomes observed in patients using DHIs designed for brain-gut behavior skills and health monitoring were consistent with previous studies <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s xml:id="_y6EQ3kA">Conversely, outcome improvements from the use of diet-based DHIs were inconsistent despite diet being a crucial component of IBS management.</s><s xml:id="_RGMt8DM">However, the limited number of studies poses a challenge in evaluating the full extent of the impacts of such interventions.</s><s xml:id="_tk9sDWj">Furthermore, studies have not looked at psychological indices in relation to diet-based DHIs, as this would include GI-specific psychological processes that are likely to be relevant for diet-based interventions (e.g., fear of food, GI-specific anxiety, pain catastrophizing).</s><s xml:id="_vR6B6Ty">This relationship between food and emotional and mental well-being has been reported in people living with IBD in a recent study led by patient research partners with lived experience <ref type="bibr" target="#b67">[68]</ref>.</s><s xml:id="_Npm2GmX">Further research into their psychological impacts on IBS patients is critical in understanding the relationship and effectiveness of diet-based DHIs as self-management tools in comparison to other DHIs.</s></p><p xml:id="_9ewKFpT"><s xml:id="_fKdHnc4">Lastly, examining these relationships is further complicated by the fact that some DHIs included in this review have more than one focus area.</s><s xml:id="_7zpXc4M">Assessments based solely on a singular aspect of a DHI restricts our ability to fully understanding their impacts, and further exploration on the dynamics between multiple focus areas and effectiveness outcomes are needed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_CxXpt2c">Personalization</head><p xml:id="_wbsZU7b"><s xml:id="_eM6hKNX">Due to the heterogeneity of symptoms and patient treatment preferences, IBS management is multi-faceted and should be personalized when possible <ref type="bibr" target="#b68">[69]</ref>.</s><s xml:id="_PjeNXs4">Despite our anticipations that more personalized and customizable DHIs would correlate with significant improvements in effectiveness outcomes, the evidence suggests otherwise.</s><s xml:id="_CDqdUWB">Four of the nine DHIs categorized as personalization levels "2" or "3" noted insignificant improvements, whereas all four DHIs categorized as level "1" yielded significant improvements in effectiveness outcomes.</s><s xml:id="_f9r9kzq">This result conflicts with other literature supporting features of and the desire for personalization in DHIs <ref type="bibr" target="#b69">[70,</ref><ref type="bibr" target="#b70">71]</ref>.</s><s xml:id="_pFHf73e">However, it is important to acknowledge that the three of four "level-1" DHIs are affiliated with brain-gut behavioral skills; certain focus areas might confound our results when evaluating effectiveness outcomes in the context of personalization level.</s><s xml:id="_PDgfSwm">It is challenging to gauge the impacts of personalization and customization of DHIs in isolation, as the focus areas may dictate the design and functions of the DHI to achieve the best outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NVMqeqq">Level of Engagement</head><p xml:id="_2DvXZMG"><s xml:id="_9ufV6vT">From both patient and provider perspectives, DHIs can be an efficient and convenient platform between the two parties to communicate and optimize patient management plans <ref type="bibr" target="#b71">[72]</ref>.</s><s xml:id="_wB3rJeR">To our surprise, there were no observed differences in effects between self-directed and hybrid interventions on effectiveness outcomes, suggesting that incorporating patient-provider communication does not significantly impact the effectiveness of DHIs for IBS self-management.</s><s xml:id="_8bvqPq9">Contrary to our findings, interventions that aim to improve patient-provider communication have demonstrated improvements in population health and patient and provider experiences <ref type="bibr" target="#b72">[73]</ref>.</s><s xml:id="_zC6ZKcy">However, Drossman et al.'s assessment comprised mostly provider-focused studies, which contrasts with the selected studies and results from this review.</s><s xml:id="_65FxZHc">Including both medical professionals and IBS patients in the development of DHIs is crucial to ensure relevancy, safety, and validity of the information and assess usability and satisfaction, respectively.</s><s xml:id="_uw2TcuK">However, more research is needed to understand the patients' perspectives and priorities regarding the implementation of a hybrid, two-way communication approach to fully optimize such features and their benefits.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zgt3vDg">Feasibility</head><p xml:id="_S3krUwW"><s xml:id="_Wg9JCBj">Usability and desirability scored highly, yet adherence and attrition varied greatly.</s><s xml:id="_D3y798F">Of the studies that assessed for feasibility, studies with DHIs that focused on brain-gut behavior skills and had no capacity for personalization indicated high attrition or low completion rates <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s xml:id="_PrG5578">Considering that this type of DHI was associated with improved effectiveness outcomes, in addition to the correlation found between attrition and psychological indices <ref type="bibr" target="#b23">[24]</ref>, this finding could indicate a relation between structured brain-gut behavioral therapies, effectiveness outcomes, and attrition rates.</s><s xml:id="_hyYXRkH">Although evidence suggests that adherence and attrition of DHIs do not significantly affect effectiveness outcomes, it could be that effectiveness outcomes from brain-gut behavioral therapies, instead, affect adherence and attrition.</s><s xml:id="_effYFZg">However, considering the contrast in effectiveness outcomes between the attrited participants before the eightweek and three-month assessments <ref type="bibr" target="#b23">[24]</ref>, further investigations are needed to fully understand this relationship.</s></p><p xml:id="_zuWeDDT"><s xml:id="_8wfrhKe">It should also be noted that most DHIs assessed in this review were developed by the research teams and under short term, controlled environments free from external factors.</s><s xml:id="_dXd5xNr">It is important to consider patients' decision-making in the prolonged use of DHIs in the real-world context, such as motivation, cost, and user system fit, <ref type="bibr" target="#b73">[74]</ref><ref type="bibr" target="#b74">[75]</ref><ref type="bibr" target="#b75">[76]</ref>.</s><s xml:id="_pdgmSS7">Digital health literacy, a skill reflective of patients' sociodemographic factors <ref type="bibr" target="#b76">[77]</ref>, can also pose a barrier for some in understanding or operating DHIs <ref type="bibr" target="#b77">[78]</ref>, and by extension, maintaining their engagement.</s><s xml:id="_bByFmJg">Thus, interpretations of the influences of attrition using real-world data are complex and multi-faceted.</s><s xml:id="_SWkgt5B">While higher attrition could indicate the intervention's effectiveness and success <ref type="bibr" target="#b78">[79]</ref>, it could, alternatively, be a repercussion of behavioral and sociodemographic factors <ref type="bibr" target="#b74">[75]</ref>.</s></p><p xml:id="_u7TwkcV"><s xml:id="_4fXHMuN">Our findings on feasibility reflect existing issues of the gap in research-specifically qualitative investigations, realworld longitudinal data, and implementation science-on the utility of DHI for IBS patients in real-world practice.</s><s xml:id="_6gYrJMC">There have been encouraging efforts to explore these topics in research <ref type="bibr" target="#b79">[80]</ref>.</s><s xml:id="_c7yJdmM">However, should these questions remain unaddressed, it will be difficult to ascertain the full extent of the efficacy and application of DHIs, which could have detrimental effects on the clinical value, trust, and uptake of these tools among IBS patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2TrrhK8">Strengths and Limitations</head><p xml:id="_Yw7MQMN"><s xml:id="_eWvXEnP">This review included a rigorous methodology using thorough literature searches, multiple databases, and various MeSH terms for digital health.</s><s xml:id="_a6hA9Fg">This specific search strategy is important, given a lack of universal MeSH terms indexing for digital health.</s><s xml:id="_jxCuXpr">In addition to the database search, we screened reference lists of excluded articles to include potentially relevant studies on the topic.</s><s xml:id="_nwFJfsH">Study selection, extraction, and quality assessment were also completed in duplicate.</s><s xml:id="_qgqf8TG">Our results highlight the potential value of DHIs in IBS self-management and the need for future research to further explore how to develop and implement the most effective and feasible DHIs.</s></p><p xml:id="_M3AJup7"><s xml:id="_FhwRz5V">The results of this review should also be interpreted with several limitations in consideration.</s><s xml:id="_NG4jEqn">Study samples may not be representative of the IBS population and thus, results may not be generalizable.</s><s xml:id="_Yk5NjXw">Participant eligibility criteria, for example, may be biased toward those interested in health technology, have strong digital literacy and skills, or are proficient in English.</s><s xml:id="_dFrf25E">Furthermore, the overall safety of the DHIs was not evaluated due to the limited number of studies that have explored this outcome.</s><s xml:id="_NHaT2D8">Aspects of safety include associated risks from inaccurate, conflicting, and inadequate information or response from the intervention.</s><s xml:id="_qCpDKgs">If not addressed, such safety concerns could result in repercussions and harm patients' physical and emotional well-being <ref type="bibr" target="#b80">[81]</ref>.</s></p><p xml:id="_CDq9fEW"><s xml:id="_5bBbPf6">Although DHI features identified in this review aligned with the common aims of GI-specific mHealth apps <ref type="bibr" target="#b81">[82]</ref>, the large heterogeneity among the DHIs restricted our ability to conduct a meta-analysis and resulted in more descriptive findings for this review.</s><s xml:id="_vnEdPby">Similarly, the heterogeneity in outcome measures requires careful interpretation when making definitive conclusions about the effectiveness of any specific intervention, especially when based on the small number of studies and limited data.</s></p><p xml:id="_r4BV9B3"><s xml:id="_ESn6SYR">DHIs were designed with multiple features such that it was not possible to compare single-and multi-focused interventions.</s><s xml:id="_MQArjBy">Comparisons would require exploring potential correlations between intervention features and effectiveness outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gAtpKUE">Future Directions</head><p xml:id="_f6srHHe"><s xml:id="_nDe5ZPg">Additional research is needed to further validate the findings of IBS-focused DHIs from clinical and patient perspectives.</s><s xml:id="_yAYMtK7">The development and testing stages of the intervention should consider experimental studies with sufficient power and control groups to detect differences between groups and follow-up periods to examine maintenance or sustained use.</s><s xml:id="_9ptAtkR">Based on the current studies, it is unknown whether participants continued using DHIs, to what extent, and how longterm use could impact their outcomes.</s></p><p xml:id="_tQ2Wrw8"><s xml:id="_rCGbkrN">All pertinent parties, including patients, should be at the center of the development and iteration of DHIs.</s><s xml:id="_JF5MB3d">Patient involvement could be achieved through co-designing and user testing; qualitative studies on IBS patient experiences are also valuable in enriching our understanding and improving interventions for future iterations.</s><s xml:id="_XRDAFbQ">Studies should also include assessments of safety, cost-effectiveness, use of the healthcare resources (e.g., primary care provider and emergency department visits), and the role of user behavior change and maintenance of behavior to broaden adoption and uptake of DHIs in IBS.</s></p><p xml:id="_tzR8egS"><s xml:id="_aA4BJSm">It is also important to note that digital health technology is an emerging field.</s><s xml:id="_XdNVqsW">Nine studies (69%) included in our review were conducted within the past four years, with the earliest study published in 2011.</s><s xml:id="_K67Cuth">As more DHIs are developed and evaluated, an increased understanding of their impact will follow.</s><s xml:id="_NH3HT9s">Further research is warranted to examine effect moderators and identify potential mechanisms underlying effective DHIs that could improve patients' selfmanagement practices and overall well-being.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_w6Ey3FM">Conclusion</head><p xml:id="_kYwcpNq"><s xml:id="_K5rRrJB">The rise of digital and technological solutions for disease management and the growing evidence supporting the use of DHIs can improve patients' understanding of their disease and self-management.</s><s xml:id="_89wFnev">Although the current evidence base is still limited, our review sheds light on the use and potential of DHIs in improving patient outcomes and in being a part of meaningful multimodal strategies for self-management in IBS.</s><s xml:id="_eWaNDUf">Nevertheless, further research examining DHIs in IBS is warranted to determine which interventions are most acceptable to patients while also demonstrating the effectiveness and sustainability of their use, particularly in a clinical setting.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p xml:id="_R6tDq2k"><s xml:id="_5QTfXPG">Fig. 1 PRISMA systematic review flow diagram of studies</s></p></div></figDesc><graphic coords="4,53.86,57.76,487.56,475.68" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><figDesc><div><p xml:id="_Bacf6ea"><s xml:id="_3kw6qH6">et al. (2023) [23] Attrition (Percentage of participants who completed all study measures at baseline and end of study) Adherence &amp; attrition 20% Overall attrition rate: Control group = 12%, Intervention group = 9%.</s><s xml:id="_q9VYsaT">Adherence (Participants with class attendance of ≥ 75% considered "adherent") Adherence &amp; Attrition Average class attendance = 79% (s.d.</s><s xml:id="_ymGv2B6">20%).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><figDesc><div><p xml:id="_Q57Hee8"><s xml:id="_xKVxXrb"><ref type="bibr" target="#b25">Karkar et al. (2017)</ref> <ref type="bibr" target="#b25">[26]</ref> UBS Desirability &amp; Satisfaction Difficulty of use = 0.73(1.1),</s><s xml:id="_atrRX6F">Physical = 0.2 (0.56), Time and social = 0.5(1.35),</s><s xml:id="_P5BGt2f">Mental and emotional = 0.47 (0.9), Privacy = 0.8 (1.42).</s><s xml:id="_mWQ2eMy">UBS scores noted median of 0 and high s.d. for all subscales, indicating that most participants did not report any burden.</s><s xml:id="_bqzM7xX">Compliance rate (Number of participants engaged and compliant to the intervention) Adherence &amp; Attrition 100% compliance from 80% of participants.</s><s xml:id="_7KRZFsP">Oerlemans et al. (2011) [27] Feasibility (Completion rate in the short [4 weeks] or long term [3 months]) Adherence &amp; Attrition Completion of the diary in the short term is considered feasible, but not in the long term due to high dropout rates.</s><s xml:id="_wMjU3BW">Pathipati et al. (2024) [28] Adherence (Number of users who finished at least 5 sessions, considered "adherent") Adherence &amp; Attrition Number of users who were considered "adherent" = 324 (38%).</s><s xml:id="_bMxKJaH">Of the initial 843 participants, 324 (38%) completed half-way of the program (5 sessions) and 162 (19%) completed all 10 sessions.</s><s xml:id="_hfQDWh7">Peters et al. (2023) [29] Completion rate (Average time of program completion) Adherence &amp; Attrition Average time completion: ~ 50 days (range 44-69).</s><s xml:id="_a4x4mkv">2843 users participated in the 1-week free trial, 1427 (50%) purchased the full program, 283 (18%) completed all 42 sessions.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s xml:id="_HM2uFcC">Descriptions and examples of the focus areas in DHIsDHI digital health intervention, CBT cognitive behavioral therapy</s></p></div></figDesc><table><row><cell>Primary Focus Area</cell><cell>Description</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p xml:id="_tScGEvR"><s xml:id="_9Sk7PHa">Study and participant characteristics</s></p></div></figDesc><table><row><cell>Country Study duration Mean age (s.d.) Sample size Male (%) IBS subtypes Digital health inter-Categories of meas-</cell><cell>(years) vention ured outcomes</cell><cell>UK 8 weeks Median 38 (IQR 19) 20,553 20 Not reported FoodMaestro FOD-Symptoms</cell><cell>MAP app</cell><cell>USA 12 weeks 34 (14) 40 12 Not reported Self-care program Symptoms</cell><cell>Quality of life</cell><cell>Patient empowerment</cell><cell>Canada 8 weeks (8 sessions) 45.37 (14.0) 63 7.6 IBS-D Online yoga classes Feasibility</cell><cell>IBS-C Symptoms</cell><cell>IBS-M Quality of life</cell><cell>IBS-U Psychological Indices</cell><cell>USA 8 weeks 32 (10) 80 25 IBS-D Mobile app-deliv-Feasibility</cell><cell>IBS-C ered CBT program Symptoms</cell><cell>IBS-M (Zemedy) Quality of life</cell><cell>IBS-U Psychological Indices</cell><cell>USA 9 weeks 37 (Not reported) 37 38 IBS Dietary program Feasibility</cell><cell>IBS-CD Symptoms</cell><cell>IBS-UC Quality of life</cell><cell>Patient empowerment</cell><cell>USA 12 days Not reported 15 33 Not reported Dietary program Feasibility</cell><cell>(TummyTrials) Symptoms</cell><cell>Netherlands 4 weeks Intervention: 36 72 16 Not reported Health diary Feasibility</cell><cell>(12) Symptoms</cell><cell>Control: 41 (16) Quality of Life</cell><cell>Psychological Indices</cell><cell>USA 3 months Median 41 (IQR 324 Not reported IBS-D Mahana™ IBS Feasibility</cell><cell>(10 sessions) 14-85) IBS-C Symptoms</cell><cell>IBS-M Psychological Indices</cell><cell>Australia 3 months Not reported 190 23 Not reported Gut-directed hypno-Feasibility</cell><cell>(42 sessions) therapy (Nerva) Symptoms</cell><cell>USA 40 days Intervention: 27 25 12 IBS-D Dietary program Feasibility</cell><cell>(10-day pre-(10) IBS-C (Heali) Symptoms</cell><cell>treatment period, Control: 26 (12) IBS-M Quality of life</cell><cell>30-day treatment Patient empowerment</cell><cell>period)</cell><cell>Japan 8 weeks Intervention: 20 (1) 40 0 IBS-D Self-care program Symptoms</cell><cell>Control: 22 (4) IBS-C Quality of life</cell><cell>IBS-M</cell><cell>IBS-U</cell><cell>Iran 1 month Intervention: 33.56 60 43 Not reported Short-term internet-Symptoms</cell><cell>(4.83) based progressive Psychological indices</cell><cell>control: 32.61 (4.52) muscle relaxation</cell><cell>(iPMR)</cell></row><row><cell>Study design</cell><cell></cell><cell>Observational Retro-</cell><cell>spective</cell><cell>Observational Cross-</cell><cell>sectional</cell><cell></cell><cell>Experimental Rand-</cell><cell>omized Control</cell><cell></cell><cell></cell><cell>Experimental Cross-</cell><cell>over Randomized</cell><cell>Control</cell><cell></cell><cell>Observational longi-</cell><cell>tudinal</cell><cell></cell><cell></cell><cell>Experimental alter-</cell><cell>nating treatment</cell><cell>Experimental Rand-</cell><cell>omized Control</cell><cell></cell><cell></cell><cell>Observational pro-</cell><cell>spective</cell><cell></cell><cell>Observational Retro-</cell><cell>spective</cell><cell>Experimental Rand-</cell><cell>omized Control</cell><cell></cell><cell></cell><cell></cell><cell>Experimental rand-</cell><cell>omized control</cell><cell></cell><cell></cell><cell>Experimental rand-</cell><cell>omized control</cell><cell></cell><cell></cell></row><row><cell>Study</cell><cell></cell><cell>Dimidi et al. (2023)</cell><cell>[21]</cell><cell>Dorn et al. (2015)</cell><cell>[22]</cell><cell></cell><cell>D'Silva et al. (2023)</cell><cell>[23]</cell><cell></cell><cell></cell><cell>Hunt et al. (2021)</cell><cell>[24]</cell><cell></cell><cell></cell><cell>Jactel et al. (2022)</cell><cell>[25]</cell><cell></cell><cell></cell><cell>Karkar et al. (2017)</cell><cell>[26]</cell><cell>Oerlemans et al.</cell><cell>(2011) [27]</cell><cell></cell><cell></cell><cell>Pathipati et al.</cell><cell>(2024) [28]</cell><cell></cell><cell>Peters et al. (2023)</cell><cell>[29]</cell><cell>Rafferty et al.</cell><cell>(2021) [30]</cell><cell></cell><cell></cell><cell></cell><cell>Tayama et al. (2024)</cell><cell>[31]</cell><cell></cell><cell></cell><cell>Zargar et al. (2023)</cell><cell>[32]</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc><div><p xml:id="_nd9Jrxw"><s xml:id="_m5DeeAs">Digital health intervention characteristics</s></p></div></figDesc><table><row><cell>Study</cell><cell>Digital health</cell><cell>DHI platform</cell><cell>Designed by</cell><cell>Primary focus</cell><cell>Prompts for con-</cell><cell>Imbedded sup-</cell><cell>Level of</cell></row><row><cell></cell><cell>intervention</cell><cell></cell><cell>the authors</cell><cell>area</cell><cell>tinued engage-</cell><cell>port in DHI</cell><cell>personali-</cell></row><row><cell></cell><cell>(DHI)</cell><cell></cell><cell>of respective</cell><cell></cell><cell>ment</cell><cell>(Self-directed/</cell><cell>zation</cell></row><row><cell></cell><cell></cell><cell></cell><cell>studies</cell><cell></cell><cell></cell><cell>hybrid)</cell><cell>(1/2/3)</cell></row><row><cell>Dimidi et al.</cell><cell>Low FODMAP</cell><cell>Mobile</cell><cell>No</cell><cell>Diet</cell><cell>No</cell><cell>Self-directed</cell><cell>2</cell></row><row><cell>(2023) [21]</cell><cell>diet app</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dorn et al.</cell><cell>Self-care pro-</cell><cell>Web-based</cell><cell>Yes</cell><cell>Community</cell><cell>Yes (Weekly</cell><cell>Self-directed</cell><cell>2</cell></row><row><cell>(2015) [22]</cell><cell>gram</cell><cell></cell><cell></cell><cell>engagement</cell><cell>e-newsletters)</cell><cell></cell><cell></cell></row><row><cell>D'Silva et al.</cell><cell>Online yoga</cell><cell>Web-based</cell><cell>No</cell><cell>Physiological</cell><cell>Yes (Weekly</cell><cell>Hybrid (Yoga</cell><cell>3</cell></row><row><cell>(2023) [23]</cell><cell>classes</cell><cell></cell><cell></cell><cell>support</cell><cell>practice logs)</cell><cell>instructor)</cell><cell></cell></row><row><cell>Hunt et al.</cell><cell>Mobile app-</cell><cell>Mobile</cell><cell>No</cell><cell>Brain-gut behav-</cell><cell>No</cell><cell>Self-directed</cell><cell>1</cell></row><row><cell>(2021) [24]</cell><cell>delivered</cell><cell></cell><cell></cell><cell>ior skills</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>CBT program</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(Zemedy)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Jactel et al.</cell><cell cols="2">Dietary program Mobile</cell><cell>Yes</cell><cell>Diet</cell><cell>No</cell><cell>Self-directed</cell><cell>3</cell></row><row><cell>(2022) [25]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Karkar et al.</cell><cell>Dietary program</cell><cell>Mobile</cell><cell>Yes</cell><cell>Diet</cell><cell>Yes (Alarms)</cell><cell>Self-directed</cell><cell>2</cell></row><row><cell>(2017) [26]</cell><cell>(TummyTrials)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Oerlemans et al.</cell><cell>Health diary</cell><cell>Mobile</cell><cell>Yes</cell><cell>Health monitor-</cell><cell>Yes (Alarms)</cell><cell>Self-directed</cell><cell>2</cell></row><row><cell>(2011) [27]</cell><cell></cell><cell></cell><cell></cell><cell>ing</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pathipati et al.</cell><cell>Mobile app-</cell><cell>Mobile</cell><cell>No</cell><cell>Brain-gut behav-</cell><cell>No</cell><cell>Self-directed</cell><cell>1</cell></row><row><cell>(2024) [28]</cell><cell>delivered CBT</cell><cell></cell><cell></cell><cell>ior skills</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(Mahana™)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Peters et al.</cell><cell>Gut-directed</cell><cell>Mobile</cell><cell>No</cell><cell>Brain-gut behav-</cell><cell>No</cell><cell>Self-directed</cell><cell>1</cell></row><row><cell>(2023) [29]</cell><cell>hypnotherapy</cell><cell></cell><cell></cell><cell>ior skills</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(Nerva)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rafferty et al.</cell><cell>Dietary program</cell><cell>Mobile</cell><cell>No</cell><cell>Diet</cell><cell>Yes (Weekly</cell><cell>Hybrid (in-chat</cell><cell>3</cell></row><row><cell>(2021) [30]</cell><cell>(Heali)</cell><cell></cell><cell></cell><cell></cell><cell>reminders)</cell><cell>support)</cell><cell></cell></row><row><cell>Tayama et al.</cell><cell>Self-care pro-</cell><cell>Mobile, Web-</cell><cell>Yes</cell><cell>Education</cell><cell>No</cell><cell>Self-directed</cell><cell>1</cell></row><row><cell>(2024) [31]</cell><cell>gram</cell><cell>based</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Zargar et al.</cell><cell>Short form inter-</cell><cell>Web-based</cell><cell>Not reported</cell><cell>Physiological</cell><cell cols="2">Yes (WhatsApp) Self-directed</cell><cell>3</cell></row><row><cell>(2023) [32]</cell><cell>net-delivered</cell><cell></cell><cell></cell><cell>support</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>progressive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>muscle relaxa-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>tion (iPMR)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Zia et al. (2016)</cell><cell>Health diary</cell><cell>Mobile</cell><cell>Yes</cell><cell>Health monitor-</cell><cell>Yes (Alarms;</cell><cell>Self-directed</cell><cell>2</cell></row><row><cell>[33]</cell><cell></cell><cell></cell><cell></cell><cell>ing</cell><cell>optional)</cell><cell></cell><cell></cell></row></table><note xml:id="_yCdj99U"><p><s xml:id="_FUSxmJ4">Platform Interventions were either accessible using a smartphone and other mobile devices (mobile) or using the internet (web based), CBT cognitive behavioral therapy, iPMR internet-delivered progressive muscle relaxation Level of personalization, interventions were categorized from "1" to "3", with "1" as providing no capability to personalize, "2" as some capability to personalize, and "3" as full capability to personalize</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4</head><label>4</label><figDesc><div><p xml:id="_BsXMbg7"><s xml:id="_t5CvFGc">Reported effectiveness outcomes of intervention groups only from baseline to end of study and other findings</s></p></div></figDesc><table><row><cell>Other findings and com-</cell><cell>ments</cell><cell>Likert scale assessed the</cell><cell>number of participants</cell><cell>who have reported overall</cell><cell>symptoms: Initial number</cell><cell>of participants = 11,689</cell><cell>(57%), final number of</cell><cell>participants = 9105 (44%).</cell><cell>SGA: ~ 75% of participants</cell><cell>noted at least some relief</cell><cell>from baseline from the</cell><cell>adequate relief ques-</cell><cell>tion, with ~ 5% reported</cell><cell>significant relief, ~ 23%</cell><cell cols="2">moderate relief, and ~ 50%</cell><cell cols="2">a little relief.</cell><cell cols="2">Raw scores of FBDSI at</cell><cell cols="2">baseline were collected</cell><cell cols="2">but were not reported;</cell><cell cols="2">end-of-study survey did</cell><cell cols="2">not include FBDSI out-</cell><cell cols="2">come measurement.</cell><cell cols="2">Adequate relief question:</cell><cell>25 (63%) participants</cell><cell>reported adequate relief</cell><cell>of symptoms at baseline</cell><cell>and 30 (75%) at the end of</cell><cell>the study.</cell><cell>No statistically significant</cell><cell>correlations between</cell><cell>change in PAM and</cell><cell>change in IBS-QOL nor</cell><cell>satisfactory relief scales</cell><cell>scores.</cell><cell>NA</cell></row><row><cell>Statistical signifi-</cell><cell>cance (Yes/No/ NA)</cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Yes</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">No</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Yes</cell><cell cols="2">NA</cell><cell>NA</cell><cell></cell><cell>No</cell><cell>No</cell><cell>Yes</cell><cell>No</cell><cell>No</cell><cell>No</cell><cell>Yes</cell><cell>No</cell></row><row><cell>Values at baseline (s.d.) Values at end of study</cell><cell>(s.d.)</cell><cell>See "Other Findings and Comments"</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>47.1 (22.1) 77.4 (12.4)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">59.6 (10.5) 62.0 (9.6)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">63.3 (19.3) 68.2 (19.4)</cell><cell cols="2">Not reported NA</cell><cell>NA See "Other Findings and</cell><cell>Comments"</cell><cell>See "Other Findings and Comments"</cell><cell>225.2 (90.7) 200.5 (103.9)</cell><cell>87.6 (21.9) 75.9 (22.1)</cell><cell>5.9 (3.5) 5.9 (3.7)</cell><cell>7.5 (3.6) 7.0 (4.0)</cell><cell>6.6 (2.3) 4.3 (3.6)</cell><cell>20.2 (17.1) 11.7 (10.9)</cell><cell>12.8 (3.1) 10.9 (3.6)</cell></row><row><cell>Study, Year Relevant outcome measure Category of outcome</cell><cell>measure</cell><cell>Dimidi et al. (2023)[21] Likert Scale (4 point) Symptoms</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Dorn et al. (2015) [22] VAS (IBS Self-reported Patient empowerment</cell><cell>knowledge, between</cell><cell>0 = "no knowledge at all"</cell><cell>and 100 = "extremely</cell><cell>knowledgeable")</cell><cell cols="2">PAM (Patient Activation Patient empowerment</cell><cell cols="2">Measure; cumulative</cell><cell cols="2">score ranges between</cell><cell cols="2">0 = "no activation in</cell><cell cols="2">self-management" and</cell><cell cols="2">100 = "highest level of</cell><cell cols="2">activation in self-man-</cell><cell cols="2">agement")</cell><cell cols="2">IBS-QOL Quality of life</cell><cell cols="2">FBDSI Symptoms</cell><cell>SGA ("satisfactory relief Symptoms</cell><cell>scale")</cell><cell>Adequate relief question Symptoms</cell><cell>("In the past 7 days have</cell><cell>you had adequate relief</cell><cell>of your gastrointestinal</cell><cell>symptoms")</cell><cell>D'Silva et al. (2023) [23] IBS-SSS Symptoms</cell><cell>IBS-QOL Quality of life</cell><cell>GAD-7 Psychological indices</cell><cell>PHQ-9 Psychological indices</cell><cell>PSS Psychological indices</cell><cell>CSS Psychological indices</cell><cell>PHQ-15 Psychological indices</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5</head><label>5</label><figDesc><div><p xml:id="_5dUz28y"><s xml:id="_nhfaFps">Reported effectiveness outcomes between control and intervention groups by the end of the study in randomized controlled trials</s></p></div></figDesc><table><row><cell>Study, year</cell><cell>Cohorts</cell><cell>Relevant outcome</cell><cell>Category of out-</cell><cell>Control cohort</cell><cell>Intervention cohort</cell><cell>Statistical sig-</cell></row><row><cell></cell><cell></cell><cell>measurement</cell><cell>come measure</cell><cell>values (SD)</cell><cell>values (SD)</cell><cell>nificance (Yes /</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>No)</cell></row><row><cell>D'Silva et al.</cell><cell>Advice-only group</cell><cell>IBS-SSS</cell><cell>Symptoms</cell><cell>213.5 (98.5)</cell><cell>200.5 (103.9)</cell><cell>No</cell></row><row><cell>(2023)[23]</cell><cell>(Control); Yoga intervention group</cell><cell>IBS-QOL GAD-7</cell><cell>Quality of life indices Psychological</cell><cell>78.3 (28.0) 6.1 (5.6)</cell><cell>75.9 (22.1) 5.9 (3.7)</cell><cell>Yes No</cell></row><row><cell></cell><cell></cell><cell>PHQ-9</cell><cell>Psychological</cell><cell>7.1 (4.6)</cell><cell>7.0 (4.0)</cell><cell>No</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>PSS</cell><cell>Psychological</cell><cell>6.2 (3.4)</cell><cell>4.3 (3.6)</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>CSS</cell><cell>Psychological</cell><cell>16.1 (12.6)</cell><cell>11.7 (10.9)</cell><cell>No</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>PHQ-15</cell><cell>Psychological</cell><cell>11.9 (4.1)</cell><cell>10.9 (3.6)</cell><cell>No</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hunt et al. (2021)</cell><cell>Waitlisted (Crosso-</cell><cell>GSRS-IBS</cell><cell>Symptoms</cell><cell>38.18 (10.79)</cell><cell>27.56 (10.12)</cell><cell>Yes</cell></row><row><cell>[24]</cell><cell>ver Control); Immediate Inter-vention group</cell><cell>IBS-QOL FFQ</cell><cell>Quality of life indices Psychological</cell><cell>58.19 (18.53) 53.75 (18.08)</cell><cell>34.25 (19.78) 41.22 (22.23)</cell><cell>Yes Yes</cell></row><row><cell></cell><cell></cell><cell>VSI</cell><cell>Psychological</cell><cell>53.57 (12.37)</cell><cell>38.14 (16.21)</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>GI-COG</cell><cell>Psychological</cell><cell>40.84 (11.23)</cell><cell>22.44 (13.72)</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>DASS</cell><cell>Psychological</cell><cell>Depression = 15.45</cell><cell>Depression = 7.83</cell><cell>Depression: Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell>(10.39)</cell><cell>(7.88)</cell><cell>Anxiety: No</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Anxiety = 18.82</cell><cell>Anxiety = 12.72</cell><cell>Stress: Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(9.99)</cell><cell>(8.65)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Stress = 12.05</cell><cell>Stress = 8.67 (6.38)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(9.72)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>PHQ-9</cell><cell>Psychological</cell><cell>10.32 (4.29)</cell><cell>5.78 (4.20)</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Oerlemans et al.</cell><cell>Standard care</cell><cell>CSFBD</cell><cell>Psychological</cell><cell>75.90 (16.69)</cell><cell>70.83 (18.67)</cell><cell>No</cell></row><row><cell>(2011) [27]</cell><cell>group (Control);</cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Intervention group</cell><cell>IBS-QOL</cell><cell>Quality of life</cell><cell>79.62 (7.6)</cell><cell>78.60 (9.31)</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>PCS</cell><cell>Psychological</cell><cell>24.13 (5.1)</cell><cell>23.57 (5.13)</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>5pt Likert Scale</cell><cell>Symptoms</cell><cell>1.89 (0.45)</cell><cell>1.46 (0.43)</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>(Abdominal</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>pain, between</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>1 = "no pain and</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>5 = "serious inter-</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>fering pain")</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rafferty et al.</cell><cell>Standard education</cell><cell>IBS-SSS</cell><cell>Symptoms</cell><cell>Change in score:</cell><cell>Change in score:</cell><cell>No</cell></row><row><cell>(2021)[30]</cell><cell>materials group</cell><cell></cell><cell></cell><cell>-123 (NA)</cell><cell>-165 (NA)</cell><cell></cell></row><row><cell></cell><cell>(Control); Intervention group</cell><cell>WHO-QOL</cell><cell>Quality of life</cell><cell>7.0 (NA) Change in score:</cell><cell>21.5 (NA) Change in score:</cell><cell>Yes</cell></row><row><cell></cell><cell></cell><cell>LFDK</cell><cell>Patient empower-</cell><cell>Change in score:</cell><cell>Change in score:</cell><cell>No</cell></row><row><cell></cell><cell></cell><cell></cell><cell>ment</cell><cell>-6.0 (NA)</cell><cell>-14.0 (NA)</cell><cell></cell></row><row><cell>Tayama et al.</cell><cell>Standard care</cell><cell>IBS-SSS</cell><cell>Symptoms</cell><cell>205.9 (77.5)</cell><cell>131.9 (55.3)</cell><cell>Yes</cell></row><row><cell>(2024)[31]</cell><cell>group (Control); Intervention</cell><cell>IBS-QOL</cell><cell>Quality of life</cell><cell>77.5 (13.8)</cell><cell>88.1 (10.8)</cell><cell>Yes</cell></row><row><cell></cell><cell>group</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Zargar et al. (2023)</cell><cell>Psychoeducation</cell><cell>FMI-SF</cell><cell>Psychological</cell><cell>43.06 (7.12)</cell><cell>51.23 (11.7)</cell><cell>Yes</cell></row><row><cell>[32]</cell><cell>group (Control);</cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Intervention group</cell><cell>GSRS-IBS VSI</cell><cell>Symptoms Psychological</cell><cell>43.27 (10.73) 37.85 (11.6)</cell><cell>32.33 (8.21) 26.9 (6.45)</cell><cell>Yes Yes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>indices</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 6</head><label>6</label><figDesc><div><p xml:id="_KayxhcU"><s xml:id="_XSAJGKe">Reported feasibility outcomes</s></p></div></figDesc><table><row><cell>Study, year</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_s47ZEGH">Acknowledgments</head><p xml:id="_RW9NbZ5"><s xml:id="_99JZ3SP">We would like to thank our patient partner, <rs type="person">Chantel Wicks</rs> (<rs type="affiliation">CW</rs>), for contributing to the data collection and extraction for this systematic review.</s></p></div>
			</div>
			<div type="funding">
<div xml:id="_mfjM6Cb"><p xml:id="_vkt4DqZ"><s xml:id="_s6nQHJP">Funding This research was supported in full by <rs type="funder">IMAGINE</rs>, a <rs type="funder">Canadian Institutes for Health Research (CIHR) Strategy for Patient-Oriented Research (SPOR) Network</rs> (Funding Reference Number: <rs type="grantNumber">1715-000-001</rs>) with funding from several partners.</s><s xml:id="_58j7m5n">No other financial arrangements were related to the research or assistance with manuscript preparation.</s><s xml:id="_wEnWsFQ">DAM is supported by the <rs type="funder">Svare Chair in Health Economics</rs>.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_EWcY3GC">
					<idno type="grant-number">1715-000-001</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kgUABXn">Data availability</head><p xml:id="_2mYzMnk"><s xml:id="_zQ9un3K">No datasets were generated or analyzed during the current study.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dkYgbMZ">Supplementary Information</head><p xml:id="_fs9QaAw"><s xml:id="_rtgCjUq">The online version contains supplementary material available at <ref type="url" target="https://doi.org/10.1007/s10620-024-08672-7">https:// doi. org/ 10. 1007/ s10620-024-08672-7</ref>.</s></p><p xml:id="_tMF2uqQ"><s xml:id="_JH7qbws">Authors contributions AD, DAM, MVM, JS, and NH conceptualized and designed the study.</s><s xml:id="_6Qf2UEj">AD and NH conducted literature searches.</s><s xml:id="_j9wubed">NH and patient partner CW screened articles and extracted data.</s><s xml:id="_gnw6Veh">AD and NH wrote the first draft of the manuscript.</s><s xml:id="_sT3Rmef">All other authors provided revisions to subsequent drafts.</s><s xml:id="_vsad5Vq">All authors contributed to and have approved the final manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kJS6wZj">Declarations</head><p xml:id="_beRrF4C"><s xml:id="_Wcdzp6J">Conflict of interest DAM reports personal fees from the Office of Health Economics, Astellas, and Novartis and meeting expenses from Illumina.</s><s xml:id="_9stqnB9">AD, MVM, JS, and NH disclose no conflicts of interest.</s></p><p xml:id="_Wu8vhr3"><s xml:id="_MwH93qK">Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.</s><s xml:id="_3qB6zKy">The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.</s><s xml:id="_FedTERm">If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.</s><s xml:id="_6rwTZKE">To view a copy of this licence, visit <ref type="url" target="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ref>.</s></p><p xml:id="_Uz9Pj5w"><s xml:id="_pk6X4W9">Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_2nXSfEB">Global burden of irritable bowel syndrome: trends, predictions and risk factors</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Ford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SavV6D9">Nat Rev Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="473" to="486" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepa- tol. 2020;17:473-486.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_FmY6Gm9">Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Oka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Parr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barberio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">V</forename><surname>Savarino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Ford</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2468-1253(20)30217-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QExAdBE">Lancet Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">510</biblScope>
			<biblScope unit="page" from="908" to="917" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;510:908-917.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_NRzcaND">Effects of self-management interventions in patients with irritable bowel syndrome: systematic review</title>
		<author>
			<persName><forename type="first">X</forename><surname>Cong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Bernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Starkweather</surname></persName>
		</author>
		<idno type="DOI">10.1177/0193945917727705</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UNF2D5J">West J Nurs Res</title>
		<imprint>
			<biblScope unit="volume">4011</biblScope>
			<biblScope unit="page" from="1698" to="1720" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cong X, Perry M, Bernier KM, Young EE, Starkweather A. Effects of self-management interventions in patients with irri- table bowel syndrome: systematic review. West J Nurs Res. 2018;4011:1698-1720.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_UMWU3pk">Canadian association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Moayyedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Macqueen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XByxSM3">J Can Assoc Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="6" to="29" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moayyedi P, Andrews CN, MacQueen G et al. Canadian associa- tion of gastroenterology clinical practice guideline for the man- agement of irritable bowel syndrome (IBS). J Can Assoc Gastro- enterol. 2019;21:6-29.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_pePfpq6">ACG clinical guideline: Management of irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Lacy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pimentel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Brenner</surname></persName>
		</author>
		<idno type="DOI">10.14309/ajg.0000000000001036</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_D4uG66R">Off J Am Coll Gastroenterol ACG</title>
		<imprint>
			<biblScope unit="volume">1161</biblScope>
			<biblScope unit="page" from="17" to="44" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lacy BE, Pimentel M, Brenner DM et al. ACG clinical guideline: Management of irritable bowel syndrome. Off J Am Coll Gastro- enterol ACG. 2021;1161:17-44.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_U28VyH9">What are digital public health interventions? First steps toward a definition and an intervention classification framework</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wienert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jahnel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Maaß</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jrbC4gH">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">246</biblScope>
			<biblScope unit="page">31921</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wienert J, Jahnel T, Maaß L. What are digital public health inter- ventions? First steps toward a definition and an intervention clas- sification framework. J Med Internet Res. 2022;246:e31921.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<ptr target="https://www.who.int/publications/i/item/9789240081949" />
		<title level="m" xml:id="_p2nVmFe">Classification of digital interventions, services and applications in health: a shared language to describe the uses of digital technology for health, 2nd ed. world health organization</title>
		<imprint>
			<date type="published" when="2023-06-18">2023. June 18, 2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Classification of digital interventions, services and applications in health: a shared language to describe the uses of digital technol- ogy for health, 2nd ed. world health organization, 2023. https:// www. who. int/ publi catio ns/i/ item/ 97892 40081 949. Accessed June 18, 2024.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_7hQxgZU">Editorial: mHealth tools for patient empowerment and chronic disease management</title>
		<author>
			<persName><forename type="first">P</forename><surname>Sousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Parreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Luo</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpsyg.2023.1206567</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aFCuEBN">Front Psychol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">1206567</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sousa P, Martinho R, Parreira P, Luo G. Editorial: mHealth tools for patient empowerment and chronic disease management. Front Psychol. 2023;14:1206567.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_fq69BAr">Digital health for functional gastrointestinal disorders</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Pathipati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Staller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_X9MRGwZ">Neurogastroenterol Motil</title>
		<imprint>
			<biblScope unit="volume">351</biblScope>
			<biblScope unit="page">e14296</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pathipati MP, Shah ED, Kuo B, Staller KD. Digital health for functional gastrointestinal disorders. Neurogastroenterol Motil. 2021;351:e14296.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_Y9THQxJ">Telemedicine and mobile health technology are effective in the management of digestive diseases: a systematic review</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Helsel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Markowitz</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10620-018-5054-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NmhQVfd">Dig Dis Sci</title>
		<imprint>
			<biblScope unit="volume">636</biblScope>
			<biblScope unit="page" from="1392" to="1408" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Helsel BC, Williams JE, Lawson K, Liang J, Markowitz J. Tel- emedicine and mobile health technology are effective in the man- agement of digestive diseases: a systematic review. Dig Dis Sci. 2018;636:1392-1408.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_cC6QTx4">Impact of eHealth technologies on patient outcomes: a meta-analysis of chronic gastrointestinal illness interventions</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Rohde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Noar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RDr7BY9">Transl Behav Med</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rohde JA, Barker JO, Noar SM. Impact of eHealth technologies on patient outcomes: a meta-analysis of chronic gastrointestinal illness interventions. Transl Behav Med. 2021;111:1-10.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_vMac7mj">Development and current state of digital therapeutics for irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Ladewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Kinsinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XqVmeWH">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">222</biblScope>
			<biblScope unit="page" from="222" to="234" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brenner DM, Ladewski AM, Kinsinger SW. Development and current state of digital therapeutics for irritable bowel syndrome. Clin Gastroenterol Hepatol. 2024;222:222-234.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_J8Fzkk4">Managing irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Anastasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Capili</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JkXRhaj">Am J Nurs</title>
		<imprint>
			<biblScope unit="volume">1137</biblScope>
			<biblScope unit="page" from="42" to="53" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Anastasi JK, Capili B. Managing irritable bowel syndrome. Am J Nurs. 2013;1137:42-53.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_DsfuQrx">How we design feasibility studies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Bowen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kreuter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Spring</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2009.02.002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ztjFpaX">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="452" to="457" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bowen DJ, Kreuter M, Spring B et al. How we design feasibility studies. Am J Prev Med. 2009;365:452-457.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_VHxFnC3">Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Shamseer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CxP5hEn">BMJ</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page">7647</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shamseer L, Moher D, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<idno type="DOI">10.1016/j.tsf.2006.12.011</idno>
		<ptr target="https://www.covidence.org" />
		<title level="m" xml:id="_pynZqV2">Covidence-systematic review management software</title>
		<imprint>
			<date type="published" when="2024-06-10">June 10, 2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Covidence-systematic review management software. n.d. https:// www. covid ence. org. Accessed June 10, 2024.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_5YeVrHd">The well-built clinical question: a key to evidence-based decisions</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rsa</forename><surname>Hayward</surname></persName>
		</author>
		<idno type="DOI">10.7326/acpjc-1995-123-3-a12</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FWWZkse">ACP J Club</title>
		<imprint>
			<biblScope unit="volume">1233</biblScope>
			<biblScope unit="page">A12</biblScope>
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Richardson WS, Wilson MC, Nishikawa J, Hayward RSA. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;1233:A12.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_MqeV8v2">Internet-delivered cognitive behavioral therapy in patients with irritable bowel syndrome: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Chang</surname></persName>
		</author>
		<idno type="DOI">10.2196/35260</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZD3X34K">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">246</biblScope>
			<biblScope unit="page">35260</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kim H, Oh Y, Chang SJ. Internet-delivered cognitive behavio- ral therapy in patients with irritable bowel syndrome: systematic review and meta-analysis. J Med Internet Res. 2022;246:e35260.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_wAy9ePT">Statistical significance tests</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Cox</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2125.1982.tb01987.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5Ss694s">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="325" to="331" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cox DR. Statistical significance tests. Br J Clin Pharmacol. 1982;143:325-331.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_Msvh4ex">The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Downs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Black</surname></persName>
		</author>
		<idno type="DOI">10.1136/jech.52.6.377</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qYNehmZ">J Epidemiol Community Health</title>
		<imprint>
			<biblScope unit="volume">526</biblScope>
			<biblScope unit="page" from="377" to="384" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;526:377-384.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_pbgZhZF">Gut symptoms during FODMAP restriction and symptom response to food challenges during FODMAP reintroduction: a real-world evaluation in 21,462 participants using a mobile application</title>
		<author>
			<persName><forename type="first">E</forename><surname>Dimidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Belogianni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Whelan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mce</forename><surname>Lomer</surname></persName>
		</author>
		<idno type="DOI">10.3390/nu15122683</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NxKXSu8">Nutrients</title>
		<imprint>
			<biblScope unit="volume">1512</biblScope>
			<biblScope unit="page">2683</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dimidi E, Belogianni K, Whelan K, Lomer MCE. Gut symptoms during FODMAP restriction and symptom response to food chal- lenges during FODMAP reintroduction: a real-world evaluation in 21,462 participants using a mobile application. Nutrients. 2023;1512:2683.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_G39ruDH">Development and pilot testing of an integrated, web-based self-management program for irritable bowel syndrome (IBS)</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Dorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">S</forename><surname>Palsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woldeghebriel</surname></persName>
		</author>
		<idno type="DOI">10.1111/nmo.12487</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TyTDgs2">Neurogastroenterol Motil</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page" from="128" to="134" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dorn SD, Palsson OS, Woldeghebriel M et al. Development and pilot testing of an integrated, web-based self-management pro- gram for irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2015;271:128-134.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_2vCvpjF">Meditation and yoga for irritable bowel syndrome: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">D'</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vallance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v63ufJ7">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">1182</biblScope>
			<biblScope unit="page" from="329" to="337" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">D&apos;Silva A, Marshall DA, Vallance JK et al. Meditation and yoga for irritable bowel syndrome: a randomized clinical trial. Am J Gastroenterol. 2023;1182:329-337.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_sMdYzPp">Efficacy of zemedy, a mobile digital therapeutic for the self-management of irritable bowel syndrome: crossover randomized controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Miguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dukas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Onwude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>White</surname></persName>
		</author>
		<idno type="DOI">10.2196/26152</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Mw4vt8S">JMIR MHealth UHealth</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page">26152</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hunt M, Miguez S, Dukas B, Onwude O, White S. Efficacy of zemedy, a mobile digital therapeutic for the self-management of irritable bowel syndrome: crossover randomized controlled trial. JMIR MHealth UHealth. 2021;95:e26152.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_Nven7fW">Efficacy of a digital personalized elimination diet for the self-management of irritable bowel syndrome and comorbid irritable bowel syndrome and inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Jactel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Olson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Wolin</surname></persName>
		</author>
		<idno type="DOI">10.14309/ctg.0000000000000545</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M7QnYjr">Clin Transl Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page">e00545</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jactel SN, Olson JM, Wolin KY et al. Efficacy of a digital person- alized elimination diet for the self-management of irritable bowel syndrome and comorbid irritable bowel syndrome and inflamma- tory bowel disease. Clin Transl Gastroenterol. 2022;141:e00545.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_JarS6Ef">Tummytrials: a feasibility study of using self-experimentation to detect individualized food triggers</title>
		<author>
			<persName><forename type="first">R</forename><surname>Karkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Epstein</surname></persName>
		</author>
		<idno type="DOI">10.1145/3025453.3025480</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_ycbBM8D">Proc SIGCHI Conf Hum Factors Comput Syst CHI Conf</title>
		<meeting>SIGCHI Conf Hum Factors Comput Syst CHI Conf</meeting>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="volume">2017</biblScope>
			<biblScope unit="page" from="6850" to="6863" />
		</imprint>
	</monogr>
	<note type="raw_reference">Karkar R, Schroeder J, Epstein DA et al. Tummytrials: a feasibility study of using self-experimentation to detect individualized food triggers. Proc SIGCHI Conf Hum Factors Comput Syst CHI Conf. 2017;2017:6850-6863.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_ZkQCj5G">Intervening on cognitions and behavior in irritable bowel syndrome: a feasibility trial using PDAs</title>
		<author>
			<persName><forename type="first">S</forename><surname>Oerlemans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Van Cranenburgh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P-J</forename><surname>Herremans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Spreeuwenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Dulmen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ujWTvdD">J Psychosom Res</title>
		<imprint>
			<biblScope unit="volume">703</biblScope>
			<biblScope unit="page" from="267" to="277" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Oerlemans S, van Cranenburgh O, Herremans P-J, Spreeuwenberg P, van Dulmen S. Intervening on cognitions and behavior in irrita- ble bowel syndrome: a feasibility trial using PDAs. J Psychosom Res. 2011;703:267-277.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_tPfu9UR">Real-world outcomes for a digital prescription mobile application for adults with irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Pathipati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Griser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Staller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q5GSFw8">Neurogastroenterol Motil</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page">e14811</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pathipati MP, Scott LL, Griser AC, Staller K. Real-world out- comes for a digital prescription mobile application for adults with irritable bowel syndrome. Neurogastroenterol Motil. 2024;367:e14811.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_xgnvWBF">Smartphone app-delivered gut-directed hypnotherapy improves symptoms of self-reported irritable bowel syndrome: a retrospective evaluation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Halmos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AU3UMr2">Neurogastroenterol Motil</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page">14533</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Peters SL, Gibson PR, Halmos EP. Smartphone app-delivered gut-directed hypnotherapy improves symptoms of self-reported irritable bowel syndrome: a retrospective evaluation. Neurogas- troenterol Motil. 2023;354:e14533.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_hCp38Ky">A novel mobile app (Heali) for disease treatment in participants with irritable bowel syndrome: randomized controlled pilot trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Rafferty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Johnston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6jWtnT3">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">233</biblScope>
			<biblScope unit="page">24134</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rafferty AJ, Hall R, Johnston CS. A novel mobile app (Heali) for disease treatment in participants with irritable bowel syn- drome: randomized controlled pilot trial. J Med Internet Res. 2021;233:e24134.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_scpnD4F">Efficacy of an eHealth self-management program in reducing irritable bowel syndrome symptom severity: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koizumi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sj92hMb">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page">4</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tayama J, Hamaguchi T, Koizumi K et al. Efficacy of an eHealth self-management program in reducing irritable bowel syn- drome symptom severity: a randomized controlled trial. Sci Rep. 2024;141:4.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_dGvveWw">Comparing the effect of internet-delivered short-term progressive muscle relaxation and psychoeducation on mindful ability, visceral hypersensitivity and symptoms of patients with irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">F</forename><surname>Zargar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nikgoftar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Tarrahi</surname></persName>
		</author>
		<idno type="DOI">10.4103/jehp.jehp_1734_22</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UjebHH7">J Educ Health Promot</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">259</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zargar F, Fahim A, Nikgoftar N, Tarrahi MJ. Comparing the effect of internet-delivered short-term progressive muscle relaxation and psychoeducation on mindful ability, visceral hypersensitivity and symptoms of patients with irritable bowel syndrome. J Educ Health Promot. 2023;12:259.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_HatGADW">Feasibility and usability pilot study of a novel irritable bowel syndrome food and gastrointestinal symptom journal smartphone app</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Munson</surname></persName>
		</author>
		<idno type="DOI">10.1038/ctg.2016.9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mfNzw9T">Clin Transl Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page">e147</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zia J, Schroeder J, Munson S et al. Feasibility and usability pilot study of a novel irritable bowel syndrome food and gastrointesti- nal symptom journal smartphone app. Clin Transl Gastroenterol. 2016;73:e147.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_wyFfdjy">Meditation and yoga for irritable bowel syndrome: study protocol for a randomised clinical trial (MY-IBS study)</title>
		<author>
			<persName><forename type="first">D'</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Vallance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nUUA6Cs">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page">59604</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">D&apos;Silva A, Marshall DA, Vallance J et al. Meditation and yoga for irritable bowel syndrome: study protocol for a randomised clinical trial (MY-IBS study). BMJ Open. 2022;125:e059604.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_wfVuEzT">The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Whorwell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rhPpUfa">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="395" to="402" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Francis CY, Morris J, Whorwell PJ. The irritable bowel sever- ity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;112:395-402.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_VPsRRRw">Functional bowel disorders</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Drossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Toner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9FRYH2b">Dig Dis Sci</title>
		<imprint>
			<biblScope unit="volume">405</biblScope>
			<biblScope unit="page" from="986" to="995" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Drossman DA, Li Z, Toner BB et al. Functional bowel disorders. Dig Dis Sci. 1995;405:986-995.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_dBnNhVn">An irritable bowel syndrome-specific symptom questionnaire: development and validation</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">K</forename><surname>Wiklund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fullerton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Hawkey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7uEW2wg">Scand J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">389</biblScope>
			<biblScope unit="page" from="947" to="954" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wiklund IK, Fullerton S, Hawkey CJ et al. An irritable bowel syndrome-specific symptom questionnaire: development and vali- dation. Scand J Gastroenterol. 2003;389:947-954.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_GYB5H2G">Subject&apos;s global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Müller-Lissner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Koch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Talley</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0895-4356(03)00027-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pe8YJvb">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">564</biblScope>
			<biblScope unit="page" from="310" to="316" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Müller-Lissner S, Koch G, Talley NJ et al. Subject&apos;s global assess- ment of relief: an appropriate method to assess the impact of treat- ment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol. 2003;564:310-316.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_BuZQFdp">A simple clinical colitis activity index</title>
		<author>
			<persName><forename type="first">R</forename><surname>Walmsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ayres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pounder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Allan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Futp4MQ">Gut</title>
		<imprint>
			<biblScope unit="volume">431</biblScope>
			<biblScope unit="page" from="29" to="32" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Walmsley R, Ayres R, Pounder R, Allan R. A simple clinical colitis activity index. Gut. 1998;431:29-32.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_aGwdYwa">Development and validation of an inflammatory bowel diseases monitoring index for use with mobile health technologies</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Van Deen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Van Der Meulen-De Jong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Parekh</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cgh.2015.10.035</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2haSjcd">Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc</title>
		<imprint>
			<biblScope unit="volume">1412</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1742" to="1750" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Van Deen WK, van der Meulen-de Jong AE, Parekh NK et al. Development and validation of an inflammatory bowel diseases monitoring index for use with mobile health technologies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;1412:1742-1750.e7.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_K8pQJu2">Quality of life in persons with irritable bowel syndrome (development and validation of a new measure)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Patrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Drossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">O</forename><surname>Frederick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dicesare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Puder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TVBeP3N">Dig Dis Sci</title>
		<imprint>
			<biblScope unit="volume">432</biblScope>
			<biblScope unit="page" from="400" to="411" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Patrick DL, Drossman DA, Frederick IO, Dicesare J, Puder KL. Quality of life in persons with irritable bowel syndrome (development and validation of a new measure). Dig Dis Sci. 1998;432:400-411.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<ptr target="https://www.who.int/tools/whoqol" />
		<title level="m" xml:id="_H4yqScm">WHOQOL-measuring quality of life</title>
		<imprint>
			<publisher>WHOQOL meas qual life</publisher>
			<date type="published" when="2023-06-01">2023. June 1, 2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">The World Health Organization. WHOQOL-measuring qual- ity of life. WHOQOL meas qual life. 2023. https:// www. who. int/ tools/ whoqol. Accessed June 1, 2024.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_6HMGJZZ">The hospital anxiety and depression scale</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Zigmond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Snaith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_w7YsJzE">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">676</biblScope>
			<biblScope unit="page" from="361" to="370" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;676:361-370.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_ye5BZww">If I could survive without eating, it would be a huge relief&quot;: development and initial validation of the fear of food questionnaire</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Zickgraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Loftus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gibbons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Hunt</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.appet.2021.105808</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QS3BqPk">Appetite</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page">105808</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zickgraf HF, Loftus P, Gibbons B, Cohen LC, Hunt MG. &quot;If I could survive without eating, it would be a huge relief&quot;: devel- opment and initial validation of the fear of food questionnaire. Appetite. 2022;169:105808.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_QW3Ee3K">The visceral sensitivity index: development and validation of a gastrointestinal symptom-specific anxiety scale</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Labus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bolus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rEJqHkE">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">201</biblScope>
			<biblScope unit="page" from="89" to="97" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Labus JS, Bolus R, Chang L et al. The visceral sensitivity index: development and validation of a gastrointestinal symptom-spe- cific anxiety scale. Aliment Pharmacol Ther. 2004;201:89-97.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_jzbNPmE">The development of a cognitive scale for functional bowel disorders</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Toner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Stuckless</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Downie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Emmott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Akman</surname></persName>
		</author>
		<idno type="DOI">10.1097/00006842-199807000-00017</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vAhHvXq">Psychosom Med</title>
		<imprint>
			<biblScope unit="volume">604</biblScope>
			<biblScope unit="page" from="492" to="497" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Toner BB, Stuckless N, Ali A, Downie F, Emmott S, Akman D. The development of a cognitive scale for functional bowel disorders. Psychosom Med. 1998;604:492-497.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_sEa6cG8">The PHQ-9</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kroenke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Spitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jbw</forename><surname>Williams</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1525-1497.2001.016009606.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Bx8n4QZ">J Gen Intern Med</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="606" to="613" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;169:606-613.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_NbjwpWd">The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kroenke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Spitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jbw</forename><surname>Williams</surname></persName>
		</author>
		<idno type="DOI">10.1097/00006842-200203000-00008</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DwV9ZKU">Psychosom Med</title>
		<imprint>
			<biblScope unit="volume">642</biblScope>
			<biblScope unit="page">258</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;642:258.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_mJT36xV">A brief measure for assessing generalized anxiety disorder: The GAD-7</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Spitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kroenke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jbw</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Löwe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9YGQTsA">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">16610</biblScope>
			<biblScope unit="page" from="1092" to="1097" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief meas- ure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med. 2006;16610:1092-1097.</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_HkWeRXK">Development and validation of the GI-cognitions questionnaire</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ertel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Coello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rodriguez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zFXMZqb">Cogn Ther Res</title>
		<imprint>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="472" to="482" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hunt MG, Ertel E, Coello JA, Rodriguez L. Development and validation of the GI-cognitions questionnaire. Cogn Ther Res. 2014;384:472-482.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_6CTQBNS">The pain catastrophizing scale: development and validation</title>
		<author>
			<persName><forename type="first">Mjl</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pivik</surname></persName>
		</author>
		<idno type="DOI">10.1037//1040-3590.7.4.524</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wZwsYQH">Psychol Assess</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="524" to="532" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sullivan MJL, Bishop SR, Pivik J. The pain catastrophiz- ing scale: development and validation. Psychol Assess. 1995;74:524-532.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_zTmKTwY">Development and initial validation of the COVID stress scales</title>
		<author>
			<persName><forename type="first">S</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Landry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Paluszek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Fergus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mckay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gjg</forename><surname>Asmundson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5XpuvDw">J Anxiety Disord</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page">102232</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Taylor S, Landry CA, Paluszek MM, Fergus TA, McKay D, Asmundson GJG. Development and initial validation of the COVID stress scales. J Anxiety Disord. 2020;72:102232.</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_tA9hjx9">Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Hibbard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stockard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Mahoney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tusler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p6dE7K6">Health Serv Res</title>
		<imprint>
			<biblScope unit="volume">394</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1005" to="1026" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;394p1:1005-1026.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_4tgmpHk">A comparison of a patient enablement instrument (PEI) against two established satisfaction scales as an outcome measure of primary care consultations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Howie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Heaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maxwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Walker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FRTRsZZ">Fam Pract</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="165" to="171" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Howie JG, Heaney DJ, Maxwell M, Walker JJ. A comparison of a patient enablement instrument (PEI) against two established satisfaction scales as an outcome measure of primary care con- sultations. Fam Pract. 1998;152:165-171.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_hTBvZ8t">A short food literacy questionnaire (SFLQ) for adults: findings from a swiss validation study</title>
		<author>
			<persName><forename type="first">Gréa</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Beer-Borst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sommerhalder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hayoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Abel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RNrWNUk">Appetite</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="275" to="280" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gréa Krause C, Beer-Borst S, Sommerhalder K, Hayoz S, Abel T. A short food literacy questionnaire (SFLQ) for adults: find- ings from a swiss validation study. Appetite. 2018;120:275-280.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<idno type="DOI">10.29219/fnr.v68.10366</idno>
		<ptr target="https://epi.grants.cancer.gov/diet/usualintakes/ffq.html" />
		<title level="m" xml:id="_zxUz92f">NHANES Food Questionnaire</title>
		<meeting><address><addrLine>FFQ</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2021-06-18">2021. June 18, 2024</date>
		</imprint>
		<respStmt>
			<orgName>National Cancer Institute</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">National Cancer Institute. NHANES Food Questionnaire (FFQ). 2021. https:// epi. grants. cancer. gov/ diet/ usual intak es/ ffq. html. Accessed June 18, 2024.</note>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title level="m" type="main" xml:id="_Udv7m2f">A &quot;Quick and Dirty&quot; Usability Scale</title>
		<author>
			<persName><forename type="first">Brooke</forename><forename type="middle">J</forename><surname>Sus</surname></persName>
		</author>
		<idno type="DOI">10.1201/9781498710411-35</idno>
		<editor>PW Jordan B Thomas B Weerdmeester McClelland</editor>
		<imprint>
			<date type="published" when="1996">1996</date>
			<publisher>Taylor &amp; Francis</publisher>
			<biblScope unit="page" from="189" to="194" />
			<pubPlace>London, UK</pubPlace>
		</imprint>
	</monogr>
	<note>Usability Eval. Ind. 1st ed</note>
	<note type="raw_reference">Brooke J. SUS: A &quot;Quick and Dirty&quot; Usability Scale. PW Jor- dan B Thomas B Weerdmeester McClelland Eds Usability Eval. Ind. 1st ed., London, UK: Taylor &amp; Francis; 1996:189-94</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_YFaJYQF">Developing and validating the user burden scale: a tool for assessing user burden in computing systems</title>
		<author>
			<persName><forename type="first">H</forename><surname>Suh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shahriaree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Hekler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kientz</surname></persName>
		</author>
		<idno type="DOI">10.1145/2858036.2858448</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_nnZy2JT">Proc. 2016 CHI Conf Hum. Factors Comput</title>
		<meeting>2016 CHI Conf Hum. Factors Comput</meeting>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">2016</biblScope>
			<biblScope unit="page" from="3988" to="3999" />
		</imprint>
	</monogr>
	<note type="raw_reference">Suh H, Shahriaree N, Hekler EB, Kientz JA. Developing and validating the user burden scale: a tool for assessing user bur- den in computing systems. Proc. 2016 CHI Conf Hum. Factors Comput. 2016;2016:3988-3999.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_EnHTs7P">The net promoter score-an asset to patient experience surveys?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Krol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>De Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Delnoij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jjdjm</forename><surname>Rademakers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_E6TnvXG">Health Expect</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page" from="3099" to="3109" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Krol MW, de Boer D, Delnoij DM, Rademakers JJDJM. The net promoter score-an asset to patient experience surveys? Health Expect. 2015;186:3099-3109.</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_SYw6WSc">Digital health apps in the clinical care of inflammatory bowel disease: scoping review</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hachuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pollak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Scherl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Estrin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q2hHvuK">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">14630</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yin AL, Hachuel D, Pollak JP, Scherl EJ, Estrin D. Digital health apps in the clinical care of inflammatory bowel disease: scoping review. J Med Internet Res. 2019;19:e14630.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_zzsTHzC">mHealth intervention for improving pain, quality of life, and functional disability in patients with chronic pain: systematic review</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moreno-Ligero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Moral-Munoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Salazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Failde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VA2VJ7j">JMIR MHealth UHealth</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page">40844</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moreno-Ligero M, Moral-Munoz JA, Salazar A, Failde I. mHealth intervention for improving pain, quality of life, and functional disability in patients with chronic pain: systematic review. JMIR MHealth UHealth. 2023;111:e40844.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_ewjGFWe">Telehealth and mobile health interventions in adults with inflammatory bowel disease: a mixed-methods systematic review</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Msh</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Adatorwovor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pvwDun8">Res Nurs Health</title>
		<imprint>
			<biblScope unit="volume">441</biblScope>
			<biblScope unit="page" from="155" to="172" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Davis SP, Ross MSH, Adatorwovor R, Wei H. Telehealth and mobile health interventions in adults with inflammatory bowel disease: a mixed-methods systematic review. Res Nurs Health. 2021;441:155-172.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_G5gy5rf">EHealth technologies in inflammatory bowel disease: a systematic review</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Knowles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<idno type="DOI">10.1093/ecco-jcc/jjw059</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5hKzKaM">J Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="1103" to="1121" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jackson BD, Gray K, Knowles SR, De Cruz P. EHealth tech- nologies in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2016;109:1103-1121.</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_TSGYtUn">Utilization and effectiveness of ehealth technology in the follow-up of celiac disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Månsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meijer-Boekel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mårild</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CSftxtW">J Pediatr Gastroenterol Nutr</title>
		<imprint>
			<biblScope unit="volume">746</biblScope>
			<biblScope unit="page" from="812" to="818" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Månsson AL, Meijer-Boekel C, Mårild K. Utilization and effec- tiveness of ehealth technology in the follow-up of celiac disease. J Pediatr Gastroenterol Nutr. 2022;746:812-818.</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_pCpVNEr">Digital health technologies for remote monitoring and management of inflammatory bowel disease: a systematic review</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Atreja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8xKMzwu">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">1171</biblScope>
			<biblScope unit="page" from="78" to="97" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nguyen NH, Martinez I, Atreja A et al. Digital health tech- nologies for remote monitoring and management of inflamma- tory bowel disease: a systematic review. Am J Gastroenterol. 2022;1171:78-97.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_sfmtJhp">Patient-provider perspectives on self-management support and patient empowerment in chronic care: a mixed-methods study in a rural sub-Saharan setting</title>
		<author>
			<persName><forename type="first">V</forename><surname>Angwenyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Aantjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bunders-Aelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Lazarus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Criel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gAaeMEH">J Adv Nurs</title>
		<imprint>
			<biblScope unit="volume">7511</biblScope>
			<biblScope unit="page" from="2980" to="2994" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Angwenyi V, Aantjes C, Bunders-Aelen J, Lazarus JV, Criel B. Patient-provider perspectives on self-management support and patient empowerment in chronic care: a mixed-methods study in a rural sub-Saharan setting. J Adv Nurs. 2019;7511:2980-2994.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_evqESCf">Patient empowerment and selfmanagement behaviour of chronic disease patients: a moderated mediation model of self-efficacy and health locus of control</title>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_577nUax">J Adv Nurs</title>
		<imprint>
			<biblScope unit="volume">784</biblScope>
			<biblScope unit="page" from="1055" to="1065" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang R, Zhou C, Wu Y et al. Patient empowerment and self- management behaviour of chronic disease patients: a moderated mediation model of self-efficacy and health locus of control. J Adv Nurs. 2022;784:1055-1065.</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_swt7HXq">A patient-led, peer-to-peer qualitative study on the psychosocial relationship between young adults with inflammatory bowel disease and food</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Daley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5usNy8t">Health Expect Int J Public Particip Health Care Health Policy</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1486" to="1497" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rines J, Daley K, Loo S et al. A patient-led, peer-to-peer qualita- tive study on the psychosocial relationship between young adults with inflammatory bowel disease and food. Health Expect Int J Public Particip Health Care Health Policy. 2022;25:1486-1497.</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_36SMvRy">An approach to the care of patients with irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Farmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Ruffle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SKGgEaQ">CMAJ Can Med Assoc J</title>
		<imprint>
			<biblScope unit="volume">19211</biblScope>
			<biblScope unit="page" from="275" to="E282" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Farmer AD, Wood E, Ruffle JK. An approach to the care of patients with irritable bowel syndrome. CMAJ Can Med Assoc J. 2020;19211:E275-E282.</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_47KZ9wT">Patients&apos; perceptions of mhealth apps: meta-ethnographic review of qualitative studies</title>
		<author>
			<persName><forename type="first">V</forename><surname>Vo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Auroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sarradon-Eck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3XHfMDn">JMIR MHealth UHealth</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page">13817</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vo V, Auroy L, Sarradon-Eck A. Patients&apos; perceptions of mhealth apps: meta-ethnographic review of qualitative studies. JMIR MHealth UHealth. 2019;77:e13817.</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_aVrHCU8">Design features for improving mobile health intervention user engagement: systematic review and thematic analysis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sXYHnNg">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">2212</biblScope>
			<biblScope unit="page">21687</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wei Y, Zheng P, Deng H, Wang X, Li X, Fu H. Design features for improving mobile health intervention user engagement: systematic review and thematic analysis. J Med Internet Res. 2020;2212:e21687.</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_DDMQZ3M">The use of communication apps by medical staff in the australian health care system: survey study on prevalence and use</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nikolic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wickramasinghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Claydon-Platt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Balakrishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Smart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bgKfENy">JMIR Med Inform</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page">e9</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nikolic A, Wickramasinghe N, Claydon-Platt D, Balakrishnan V, Smart P. The use of communication apps by medical staff in the australian health care system: survey study on prevalence and use. JMIR Med Inform. 2018;61:e9.</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_NmfxY8e">A review of the evidence and recommendations on communication skills and the patient-provider relationship: a rome foundation working team report</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Drossman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Deutsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_judAAav">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">1615</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1670" to="1688" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Drossman DA, Chang L, Deutsch JK et al. A review of the evi- dence and recommendations on communication skills and the patient-provider relationship: a rome foundation working team report. Gastroenterology. 2021;1615:1670-1688.e7.</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_DdYFFRG">Rates of attrition and dropout in app-based interventions for chronic disease: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Meyerowitz-Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ravi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Arnolda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maberly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Astell-</forename><surname>Burt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7sAwN4u">Journal of Medical Internet Research</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">e20283</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Meyerowitz-Katz G, Ravi S, Arnolda L, Feng X, Maberly G, Astell-Burt T. Rates of attrition and dropout in app-based inter- ventions for chronic disease: systematic review and meta-analysis. Journal of Medical Internet Research. 2020;22:e20283.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main" xml:id="_fBTPp4u">The continued use of mobile health apps: insights from a longitudinal study</title>
		<author>
			<persName><forename type="first">I</forename><surname>Vaghefi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tulu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SauEc4r">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e12983</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vaghefi I, Tulu B. The continued use of mobile health apps: insights from a longitudinal study. JMIR Mhealth Uhealth. 2019;7:e12983.</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main" xml:id="_AT73ced">Consumer acceptance and use of information technology: extending the unified theory of acceptance and use of technology</title>
		<author>
			<persName><forename type="first">V</forename><surname>Venkatesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jyl</forename><surname>Thong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ct7fQmy">MIS Quarterly</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="157" to="178" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Venkatesh V, Thong JYL, Xu X. Consumer acceptance and use of information technology: extending the unified theory of accept- ance and use of technology. MIS Quarterly. 2012;36:157-178.</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main" xml:id="_9Gj9gKh">Sociodemographic determinants of digital health literacy: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Estrela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Semedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Roque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Herdeiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ahey3cT">Int J Med Inform</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page">105124</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Estrela M, Semedo G, Roque F, Ferreira PL, Herdeiro MT. Soci- odemographic determinants of digital health literacy: a systematic review and meta-analysis. Int J Med Inform. 2023;177:105124.</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main" xml:id="_bBq3cCN">Current challenges and potential solutions to the use of digital health technologies in evidence generation: a narrative review</title>
		<author>
			<persName><forename type="first">H</forename><surname>Mumtaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Riaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wajid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cHawGhh">Front Digit Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">1203945</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mumtaz H, Riaz MH, Wajid H et al. Current challenges and potential solutions to the use of digital health technologies in evidence generation: a narrative review. Front Digit Health. 2023;5:1203945.</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main" xml:id="_RzdsUdd">Challenges in participant engagement and retention using mobile health apps: literature review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Amagai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kaat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Nowinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Gershon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6xKpTKN">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">244</biblScope>
			<biblScope unit="page">35120</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Amagai S, Pila S, Kaat AJ, Nowinski CJ, Gershon RC. Challenges in participant engagement and retention using mobile health apps: literature review. J Med Internet Res. 2022;244:e35120.</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main" xml:id="_FDn6bAa">Perspectives on the sustained engagement with digital health tools: Protocol for a qualitative interview study among people living with inflammatory bowel disease or irritable bowel syndrome</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Olson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palumbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Desjardins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TCnr9bJ">BMJ Open</title>
		<imprint>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note>Forthcoming</note>
	<note type="raw_reference">Olson, JL, Palumbo, A, Desjardins C, et al. Perspectives on the sustained engagement with digital health tools: Protocol for a qualitative interview study among people living with inflam- matory bowel disease or irritable bowel syndrome. BMJ Open. Forthcoming 2024.</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main" xml:id="_jnQBmzQ">Safety concerns with consumerfacing mobile health applications and their consequences: a scoping review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Akbar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Enrico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Magrabi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_b2N4mjD">J Am Med Inform Assoc</title>
		<imprint>
			<biblScope unit="volume">272</biblScope>
			<biblScope unit="page" from="330" to="340" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Akbar S, Enrico C, Magrabi F. Safety concerns with consumer- facing mobile health applications and their consequences: a scop- ing review. J Am Med Inform Assoc. 2020;272:330-340.</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main" xml:id="_3QaGy3A">Mobile apps for the management of gastrointestinal diseases: systematic search and evaluation within app stores</title>
		<author>
			<persName><forename type="first">E-M</forename><surname>Messner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sturm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Terhorst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tNAS8Wh">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">2410</biblScope>
			<biblScope unit="page">37497</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Messner E-M, Sturm N, Terhorst Y et al. Mobile apps for the man- agement of gastrointestinal diseases: systematic search and evalu- ation within app stores. J Med Internet Res. 2022;2410:e37497.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
